Fact-checked by Grok 2 weeks ago

Molecular diagnostics

Molecular diagnostics encompasses laboratory techniques that analyze biological molecules, such as DNA, RNA, and proteins, to detect disease-associated changes, identify pathogens, and assess genetic risks in clinical samples.^[1]^[2] These methods enable the direct examination of genomic and proteomic markers, offering higher sensitivity and specificity than conventional microscopy or culture-based approaches for diagnosing conditions like infections, cancers, and inherited disorders.^[3]^[4] Key techniques include polymerase chain reaction (PCR) for amplifying nucleic acids, next-generation sequencing for comprehensive genetic profiling, and microarrays for high-throughput gene expression analysis.^[3]^[5] Developed from foundational advances like PCR in the 1980s, molecular diagnostics transitioned to clinical use in the 1990s, markedly improving diagnostic speed and accuracy during outbreaks and in precision oncology.^[6]^[7] Applications span infectious disease detection, where nucleic acid tests rapidly identify viral and bacterial agents; oncology, guiding targeted therapies via tumor biomarkers; and pharmacogenomics, predicting drug responses based on genetic variants.^[8]^[9]^[10] This field underpins personalized medicine by linking molecular causality to disease outcomes, though challenges like assay validation and cost persist in resource-limited settings.^[11]

History

Early Foundations and Conceptual Development

The discovery of the DNA double helix structure by James D. Watson and Francis Crick in 1953 established the molecular basis for genetic inheritance, depicting DNA as two complementary antiparallel strands twisted into a right-handed helix with adenine-thymine and guanine-cytosine base pairs stabilizing the ladder-like configuration.^[12] This model elucidated how genetic information is encoded in nucleotide sequences and replicated via semiconservative mechanisms, providing the conceptual framework for analyzing specific genetic sequences rather than relying solely on observable traits.^[13] Prior to this, genetic studies had been constrained to phenotypic observations and chromosomal cytology, but the double helix enabled predictions about sequence-specific interactions, such as hybridization between complementary strands, which later informed nucleic acid-based detection strategies.^[12] Building on this foundation, the isolation of restriction endonucleases in the late 1960s and early 1970s introduced tools for precise DNA manipulation. In 1970, Hamilton O. Smith identified the first type II restriction enzyme, HindII, from Haemophilus influenzae, which cleaves DNA at specific palindromic recognition sites, producing defined fragments.^[14] These enzymes, unlike earlier type I variants that cleaved nonspecifically, allowed reproducible cutting at known sequences, facilitating the generation of DNA maps and the study of genetic elements in isolation.^[15] This biochemical precision addressed limitations in earlier DNA handling methods, such as denaturation-renaturation, by enabling targeted fragmentation essential for dissecting genotypic variations underlying phenotypic differences.^[16] Recombinant DNA techniques emerged in the early 1970s, integrating restriction enzymes with DNA ligases to join disparate DNA fragments. Pioneered by Paul Berg in 1972 with the first hybrid molecule and advanced by Stanley N. Cohen and Herbert W. Boyer in 1973 through plasmid-based cloning in Escherichia coli, these methods permitted the propagation of foreign DNA sequences in bacterial hosts.^[17]^[18] This shift from phenotypic assays—such as microbial culturing or serological tests, which often required viable organisms and yielded indirect evidence—to direct genotypic interrogation was driven by the need for sequence-level resolution in identifying genetic determinants, particularly for pathogens where culture-dependent methods proved slow or infeasible.^[19] By the mid-1970s, these tools had laid the groundwork for isolating and amplifying specific nucleic acids, though clinical diagnostic applications remained undeveloped until later amplification innovations.^[20]

Key Technological Breakthroughs (1980s–2000s)

The polymerase chain reaction (PCR), invented by Kary Mullis in 1985, represented a foundational breakthrough in molecular diagnostics by enabling exponential amplification of specific DNA sequences from minute samples.^[21] This technique, which earned Mullis the 1993 Nobel Prize in Chemistry, overcame prior limitations in nucleic acid detection sensitivity, allowing for the identification of pathogens and genetic variants at levels previously undetectable without extensive culturing or cloning.^[21] Early validation came in 1989, when PCR was applied to detect HIV proviral DNA in peripheral blood mononuclear cells from seropositive mothers and their infants, demonstrating superior sensitivity over serological methods for early diagnosis and monitoring.^[22] In the late 1980s and early 1990s, advancements in hybridization technologies, including fluorescence in situ hybridization (FISH), enhanced the precision of molecular detection by permitting direct visualization of specific nucleic acid sequences in cells or tissues using fluorescently labeled probes.^[23] First applied in 1980 with fluorophore-labeled RNA probes, FISH evolved through the 1980s with DNA probes, enabling chromosomal aberration detection relevant to diagnostics, such as aneuploidy in prenatal testing.^[23] Concurrently, Sanger sequencing, originally developed in 1977, saw standardization for diagnostic use via automated fluorescent dye terminators in the 1990s, facilitating routine mutation analysis in clinical settings and contributing to the identification of disease-causing variants with high accuracy.^[24] The 1990s introduced DNA microarrays, with Affymetrix demonstrating in 1994 the synthesis of high-density arrays containing up to 256 probes, scaling hybridization assays to thousands of sequences simultaneously for gene expression and genotyping.^[25] This high-throughput approach accelerated diagnostic validation, as evidenced by its adoption for polymorphism detection in diseases like cystic fibrosis. Regulatory milestones followed, with the first FDA-cleared molecular diagnostic kits emerging in 1996, including assays for CFTR mutations that reduced diagnostic turnaround from months to days, enabling earlier intervention and empirical improvements in patient outcomes.^[26]

Clinical Integration and Expansion (2010s–Present)

The plummeting costs of next-generation sequencing (NGS) facilitated its transition from research to routine clinical diagnostics in the 2010s, with per-genome sequencing expenses dropping from approximately $10 million in 2007 to under $1,500 by 2015, driven largely by innovations from Illumina in high-throughput platforms like the HiSeq and NovaSeq systems.^[27]^[28] This affordability enabled widespread adoption for applications such as tumor profiling, where NGS identifies actionable mutations to guide precision oncology treatments.^[29] Integration into clinical guidelines accelerated this shift, particularly in oncology; the National Comprehensive Cancer Network (NCCN) incorporated molecular testing recommendations into its protocols, including biomarker compendia for therapies targeting mutations like EGFR in non-small cell lung cancer.^[30] Empirical data from real-world studies demonstrate survival benefits, with patients receiving molecularly matched targeted therapies exhibiting improved progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy alone—for instance, in advanced non-squamous non-small cell lung cancer cohorts, targeted inhibitor use correlated with superior 2-year PFS and OS rates.^[31] The molecular diagnostics market reflected this expansion, growing from about $4.8 billion in 2010 to over $15 billion by 2020, fueled by oncology and infectious disease applications.^[32]^[33] The COVID-19 pandemic markedly accelerated molecular diagnostics' clinical scaling, with real-time RT-PCR assays for SARS-CoV-2 rapidly deployed globally starting in early 2020, including the CDC's panel shipped to labs by February 5.^[34] This mass implementation, involving billions of tests, underscored PCR's reliability for high-volume screening and spurred investments in point-of-care (POC) molecular platforms to reduce turnaround times.^[35] Post-pandemic, expansions targeted non-respiratory indications; for example, Roche received FDA clearance and CLIA waiver in early 2025 for its cobas liat system detecting sexually transmitted infections like Chlamydia trachomatis and Neisseria gonorrhoeae at POC settings.^[36] Market projections indicate continued growth at a 9.6% CAGR through the late 2020s, driven by these integrations and regulatory advancements.^[33]

Fundamental Principles

Molecular Targets in Diagnostics

Molecular targets in diagnostics encompass biomolecules—primarily nucleic acids and proteins—whose qualitative or quantitative alterations directly reflect underlying disease pathogenesis, enabling precise identification of causal molecular defects over mere phenotypic correlations. These targets are selected based on empirical evidence linking their dysregulation to specific disease mechanisms, prioritizing those with high specificity and mechanistic causality derived from foundational studies in molecular biology. For instance, genomic DNA is targeted for its role as the heritable blueprint, where sequence variants such as single nucleotide polymorphisms (SNPs) and insertions/deletions (indels) constitutively drive inherited disorders and somatic evolution in cancers, allowing detection of predispositions that manifest predictably across generations.^[37] RNA molecules, including messenger RNA (mRNA) and non-coding RNAs, serve as dynamic indicators of transcriptional activity and pathogen presence, capturing transient states of cellular dysfunction or active replication that DNA alone cannot reveal, such as upregulated oncogenes in tumorigenesis or viral genomes in acute infections. This temporal resolution stems from RNA's rapid turnover and context-dependent abundance, which correlate with immediate pathogenic processes rather than fixed inheritance. Epigenetic modifications, like DNA methylation and histone acetylation, extend targeting capabilities by marking heritable yet reversible regulatory changes that influence gene accessibility without altering sequence, providing proxies for environmental influences on disease susceptibility when nucleic acid variants are absent or insufficient.^[38]^[39] A paradigmatic example is the BRCA1 and BRCA2 genes, whose tumor-suppressor functions in homologous recombination for DNA double-strand break repair were elucidated following their positional cloning in 1994 and 1995, respectively; germline mutations in these loci causally elevate breast cancer risk up to 72% and ovarian cancer risk up to 44% by lifetime, justifying their routine interrogation in risk stratification despite incomplete penetrance, as validated by linkage analyses in high-risk kindreds. Protein targets, such as enzymes or receptors integral to signaling cascades, complement nucleic acid-based approaches by assaying functional endpoints of molecular pathology, selected when they exhibit verifiable causal roles in disease progression, as opposed to epiphenomenal changes. Target validation emphasizes first-principles interrogation of pathway perturbations, ensuring diagnostics probe verifiable drivers of pathogenesis—e.g., loss-of-function in repair genes—over associative biomarkers lacking mechanistic depth.^[40]^[41]^[42]

Core Mechanisms of Detection and Amplification

Molecular diagnostics employ nucleic acid amplification techniques, primarily polymerase chain reaction (PCR), to generate detectable quantities of target sequences from minute initial amounts. PCR operates through repeated thermal cycles: denaturation at 94–98°C separates DNA strands by disrupting hydrogen bonds, annealing at 50–65°C allows primers to hybridize via complementary base pairing, and extension at ~72°C uses thermostable DNA polymerase (e.g., Taq from Thermus aquaticus) to synthesize new strands, incorporating dNTPs and relying on magnesium as a cofactor. Each cycle theoretically doubles the target, yielding exponential amplification—up to 2^n copies after n cycles—validated empirically in controlled reactions where product accumulation follows a sigmoidal curve with a linear exponential phase before plateauing due to substrate limits.^[43]^[44] Reverse transcription PCR (RT-PCR) extends this to RNA targets by initial cDNA synthesis using reverse transcriptase enzymes, such as those from avian myeloblastosis virus, which catalyze RNA-dependent DNA polymerization prior to standard PCR cycles. Specificity in both PCR and RT-PCR derives from Watson-Crick base pairing, where adenine pairs with thymine via two hydrogen bonds and guanine with cytosine via three, dictating primer-template affinity and minimizing mismatches; empirical melting temperature calculations (e.g., Tm = 4(G+C) + 2(A+T)) ensure hybridization under stringent conditions, reducing non-specific products as confirmed in optimization studies.^[45]^[43] Detection and quantification integrate fluorescence readouts in real-time PCR (qPCR), monitoring product accumulation cycle-by-cycle to assess signal-to-noise ratios. Intercalating dyes (e.g., SYBR Green) bind double-stranded DNA and exhibit enhanced fluorescence upon excitation, while probe-based systems like TaqMan use 5' nuclease activity to cleave fluorophore-quencher conjugates during extension, liberating signal proportional to amplicon synthesis. The cycle threshold (Ct) quantifies initial template by marking the cycle where fluorescence exceeds a baseline-subtracted threshold (typically in the exponential phase), with lower Ct indicating higher starting material; efficiency is empirically verified at 90–110% via standard curves, where ΔCt relates to fold changes via 2^{-ΔΔCt}.^[46]^[47] Amplification fidelity is constrained by physicochemical realities, including polymerase processivity limits (~10^3–10^4 bases) and inhibitors like heme, urea, or polysaccharides that sequester ions or denature enzymes, reducing yields by up to 100-fold in unpurified samples as shown in spiked-recovery experiments. Controlled studies validate these mechanisms through endpoint agarose gel verification of band intensity and qPCR efficiency plots, emphasizing extraction steps to mitigate inhibition and maintain causal chain from template to detectable signal.^[48]^[49]

Established Techniques

Nucleic Acid Amplification Methods

Nucleic acid amplification techniques enable the detection of minute quantities of genetic material in clinical samples, overcoming limitations of direct detection methods by exponentially increasing target sequences. The polymerase chain reaction (PCR), invented by Kary Mullis in 1983 while at Cetus Corporation, forms the foundation of these methods through repeated cycles of denaturation, annealing, and extension using a thermostable DNA polymerase like Taq.^[50] Initially validated in forensics for DNA genotyping and fingerprinting by the mid-1980s, PCR demonstrated reliable amplification of specific loci from degraded samples, paving the way for diagnostic applications where empirical sensitivity in controlled laboratory settings often exceeds 95% for validated assays.^[51] Endpoint PCR, the original variant, completes a fixed number of cycles before post-amplification analysis via gel electrophoresis or other visualization, providing qualitative confirmation of target presence but limited quantification due to plateau-phase inefficiencies.^[52] In contrast, real-time PCR (qPCR) incorporates fluorescent probes or dyes to monitor amplification kinetics during each cycle, enabling absolute or relative quantification and reducing contamination risks through closed-tube formats.^[53] qPCR assays typically achieve limits of detection (LOD) of 3-5 RNA or DNA copies per reaction, with analytical sensitivities reported at 95% or higher for low-prevalence targets in proficiency testing, though false positives from carryover contamination remain a concern in multi-step workflows, occurring in up to 6% of cases without uracil-N-glycosylase mitigation.^[54]^[55]^[56] Loop-mediated isothermal amplification (LAMP), developed by Notomi et al. in 2000, offers an alternative by employing 4-6 primers targeting multiple sites on the template, forming loop structures for continuous strand displacement at a constant temperature (around 60-65°C), eliminating the need for thermal cycling equipment.^[57] This simplicity suits resource-limited settings, with amplification completing in under 60 minutes and LODs comparable to PCR (often 10-100 copies/reaction), as evidenced by diagnostic studies showing sensitivities of 92-97% against qPCR benchmarks for pathogens like SARS-CoV-2.^[58]^[59] However, LAMP's reliance on complex primer sets can introduce non-specific amplification risks, yielding specificities of 94-98% in clinical evaluations, slightly lower than PCR's 99-100% in some proficiency datasets, though its closed-system potential minimizes aerosol contamination compared to traditional PCR's open post-amplification handling.^[60]^[61] Empirical trade-offs highlight PCR's superior resolution for quantitative diagnostics, with qPCR's cycle threshold (Ct) values correlating linearly to initial template abundance up to 10^6-fold dynamic range, versus LAMP's endpoint turbidity or fluorescence readouts better suited for binary detection.^[62] Proficiency testing data indicate overall PCR error rates below 5% in accredited labs, primarily from inhibition or contamination, while LAMP's isothermal nature reduces setup time but demands optimized buffers to counter variable sample matrices affecting yield.^[61]^[63] These methods' causal efficacy stems from enzymatic fidelity and primer specificity, with Taq polymerase error rates of 10^-5 per base yielding >99% accuracy over short amplicons (<500 bp), underpinning their reliability in empirical validation across diagnostics.^[64]

Sequencing and Hybridization Approaches

Sanger sequencing serves as a foundational method in molecular diagnostics for targeted validation of genetic variants, offering high resolution for sequences up to 1,000 base pairs with base-calling accuracy exceeding 99.99%.^[65] Its chain-termination approach enables precise detection of point mutations and small insertions/deletions, making it ideal for confirming variants in specific genes or amplicons, though throughput remains low at approximately one sample per capillary electrophoresis run.^[66] Empirical benchmarks position Sanger as superior for accuracy in low-complexity regions, with error rates around 1 in 10,000 bases under optimized conditions.^[67] The Human Genome Project's completion in 2003, which utilized Sanger sequencing to generate over 90% of the reference human genome, established a benchmark for diagnostic applications by facilitating alignment-based variant calling.^[68] This reference enabled subsequent diagnostic pipelines to interpret sequencing data against a complete genomic map, enhancing the causal inference of mutations in disease contexts.^[69] Fluorescence in situ hybridization (FISH) employs fluorescently labeled probes to hybridize with specific DNA sequences, providing spatial resolution for chromosomal abnormalities at scales from 50 kilobases to several megabases.^[70] In diagnostics, FISH excels in visualizing gene fusions, amplifications, and deletions within intact cells, such as in prenatal testing for aneuploidies like trisomy 21, with detection sensitivities approaching 1-5% mosaic levels in uncultured samples.^[71] Its cytogenetic specificity outperforms sequencing for structural variants requiring cellular context, though it demands intact nuclei and is limited to predefined targets.^[72] DNA microarrays facilitate high-throughput hybridization for single nucleotide polymorphism (SNP) genotyping, interrogating up to 1 million loci per array in genome-wide scans.^[73] Platforms like Affymetrix GeneChip achieve throughput for thousands of samples via automated processing, but empirical studies reveal limitations in dynamic range, often confined to 10^3 to 10^4-fold expression differences due to signal saturation and background noise.^[25] Comparative analyses with quantitative PCR demonstrate microarray underperformance in low-abundance detection, with cross-hybridization reducing specificity by up to 5-10% in polymorphic regions.^[74]

Protein and Biomarker Detection

Protein detection in molecular diagnostics primarily relies on immunoassays and mass spectrometry-based proteomics to identify and quantify biomarkers, which are measurable proteins or peptides indicative of disease states or physiological processes. Immunoassays, such as enzyme-linked immunosorbent assay (ELISA), utilize specific antibodies to bind target proteins, enabling sensitive detection down to nanomolar concentrations in complex biological samples like serum or tissue extracts.^[75] ^[76] These methods leverage antigen-antibody interactions for indirect quantification, often amplified enzymatically for high throughput in clinical settings.^[77] Mass spectrometry (MS), in contrast, provides direct structural analysis of proteins through ionization and fragmentation, facilitating proteomics workflows that compare expression profiles between healthy and diseased states to uncover biomarkers.^[78] ^[79] Techniques like surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) MS have been applied to discover panels of protein markers for conditions such as multiple sclerosis and cancer, where altered protein levels correlate with disease activity.^[80] ^[81] Proteomics thus reveals functional alterations—such as post-translational modifications or pathway dysregulations—that may not be evident from genomic data alone, establishing causal connections to pathology through empirical protein-disease associations.^[82] A prominent empirical example is prostate-specific antigen (PSA), a serine protease biomarker detected via immunoassays for prostate cancer screening. Elevated serum PSA levels (>4 ng/mL) prompt biopsies, but evidence from large-scale studies indicates substantial overdiagnosis of indolent, non-lethal tumors, with estimates suggesting 20-50% of detected cases would not progress clinically.^[83] ^[84] Randomized trials, including those analyzed in meta-reviews, show PSA screening reduces mortality modestly (by about 20% in some cohorts) but increases biopsy complications and overtreatment harms, highlighting a net harm-benefit tradeoff due to low specificity for aggressive disease.^[85] ^[86] This underscores the need for proteomic validation to refine biomarkers, integrating MS to distinguish biologically active isoforms from benign elevations. Unlike nucleic acid-based methods, which target genetic sequences for etiology, protein detection via immunoassays or MS focuses on downstream effectors, offering faster turnaround (hours vs. days) but reduced resolution for underlying mutations, as protein changes can arise from regulatory or environmental factors without genomic alterations.^[87] ^[88] In molecular pathology, these approaches complement genomics by validating pathways—e.g., correlating proteomic profiles with gene expression to confirm causal relevance in oncology or infectious diseases—yet demand rigorous empirical thresholds to mitigate false positives from assay variability or non-specific binding.^[89] Hybrid techniques, like enzyme-linked immunosorbent mass spectrometric assay (ELIMSA), combine immunoassay specificity with MS quantification for attomolar sensitivity, enhancing diagnostic precision in low-abundance biomarkers.^[90]

Emerging and Advanced Techniques

CRISPR-Based Diagnostics

CRISPR-based diagnostics adapt the RNA-guided nuclease activity of CRISPR-Cas systems, particularly Cas12 and Cas13 enzymes, to detect nucleic acid targets through sequence-specific recognition followed by collateral cleavage of reporter molecules, generating a detectable signal without relying solely on traditional amplification methods.^[91] This mechanism enables isothermal, rapid assays that combine recombinase polymerase amplification (RPA) for target enrichment with Cas-mediated readout, achieving detection limits in the attomolar range for pathogens.^[92] The approach prioritizes field-deployable simplicity, with reactions completable in under 90 minutes using lateral flow strips for visual results.^[93] The SHERLOCK platform, developed in 2017, utilizes Cas13 for RNA detection, where target binding triggers non-specific RNase activity that cleaves fluorophore-quencher reporters, producing fluorescence or colorimetric signals.^[92] DETECTR, introduced in 2018, employs Cas12a for DNA targets, leveraging similar collateral DNase activity for signal amplification.^[92] Both systems demonstrated empirical accuracy in initial validations, detecting Zika and dengue viruses in patient samples with 100% specificity and sensitivity matching qPCR in controlled settings, though requiring guide RNA design tailored to targets.^[94] Field trials have confirmed high performance, with meta-analyses of SARS-CoV-2 assays showing pooled sensitivity of 94% (95% CI: 93–95%) and specificity of 98% (95% CI: 97–99%) across over 10,000 samples, often rivaling PCR in low-viral-load scenarios when paired with sample processing like heat inactivation.^[95] For tuberculosis, CRISPR diagnostics achieved 66% sensitivity versus 98.6% specificity of GeneXpert, highlighting trade-offs in smear-negative cases but superior speed (30–60 minutes).^[96] These results underscore causal advantages in resource-limited environments, where equipment-free operation reduces costs to under $1 per test.^[97] Advancements from 2024–2025 have focused on portable point-of-care (POC) integration, including battery-powered readers and amplification-free variants for direct pathogen detection in saliva or blood.^[97] Devices like multiplexed Cas12/13 platforms detected malaria antigens and bacterial resistance genes in low-resource trials with PCR-equivalent sensitivity (10–100 copies/μL), enabling outbreak response in under 20 minutes.^[98] Such systems have been validated for zoonotic threats, with field specificity exceeding 95% in endemic areas.^[99] Despite strengths in cost and deployability, off-target risks—arising from guide RNA mismatches triggering unintended collateral cleavage—can yield false positives, as evidenced in studies where single-nucleotide variants reduced specificity by 5–10% in complex samples.^[91] Empirical data from optimized guides, however, show off-target rates below 1% in diagnostics, far lower than in genome editing contexts, due to the transient nature of detection versus permanent cuts; validation via orthogonal PCR confirms reliability in clinical cohorts.^[100] Ongoing refinements, including high-fidelity Cas variants, mitigate these empirically observed limitations without compromising speed.^[101]

Next-Generation Sequencing Applications

Next-generation sequencing (NGS) has transformed molecular diagnostics by enabling high-throughput analysis of DNA and RNA variants at reduced costs compared to traditional methods, facilitating the identification of rare genetic variants and targeted gene panels in clinical settings. Whole-exome sequencing (WES) targets the approximately 1-2% of the genome encoding proteins, detecting rare pathogenic variants associated with Mendelian disorders and undiagnosed rare diseases, with diagnostic yields reported at 20-40% in pediatric cohorts with suspected genetic conditions.^[102] Whole-genome sequencing (WGS) extends this to non-coding regions, uncovering structural variants and regulatory elements missed by WES, though its broader scope increases data complexity and interpretation challenges. In oncology, targeted NGS panels interrogate dozens to hundreds of cancer-associated genes, such as TP53, KRAS, and EGFR, to guide precision therapies by identifying actionable somatic mutations with high sensitivity for low-frequency alleles.^[103] Empirical validation demonstrates NGS reliability, with variant concordance rates exceeding 90% against Sanger sequencing, the historical gold standard, in clinical panels; studies report 100% agreement for confirmed variants in targeted assays, though discrepancies arise from sequencing depth or artifactual errors. Per-base error rates in clinical NGS workflows typically range from 0.1% to 1%, mitigated by duplicate removal, quality filtering, and coverage depths of 100-500x, ensuring robust detection of heterozygous variants at allele frequencies above 5-10%. These metrics support NGS as a scalable alternative to Sanger for multiplexing, reducing turnaround times from weeks to days while maintaining analytical validity in accredited laboratories.^[104]^[105] In liquid biopsy applications, NGS detects circulating tumor DNA (ctDNA) from plasma, enabling non-invasive monitoring of tumor evolution without tissue sampling; the U.S. FDA approved the first such test, cobas EGFR Mutation Test v2, in June 2016 for non-small cell lung cancer to identify EGFR mutations guiding tyrosine kinase inhibitor therapy. Subsequent approvals, including FoundationOne Liquid CDx in 2020 for multiple biomarkers across cancers, leverage hybrid capture NGS to quantify ctDNA variants at sensitivities down to 0.1% variant allele frequency, correlating with response rates and progression-free survival in prospective trials.^[106]^[107] NGS facilitates causal variant assessment through standardized frameworks like the American College of Medical Genetics and Genomics (ACMG) guidelines, which classify variants as pathogenic, likely pathogenic, or benign based on population frequency, computational predictions, functional data, and segregation evidence derived from deep sequencing readouts. This process integrates probabilistic scoring of evidence criteria (e.g., PVS1 for null variants in loss-of-function genes), enabling clinicians to link sequence alterations to disease phenotypes with inter-laboratory reproducibility above 90% for unambiguous cases.^[108]

Point-of-Care and Integrated Systems

Point-of-care (POC) molecular diagnostics encompass portable or near-patient devices that integrate sample preparation, nucleic acid amplification, and detection to deliver results in under an hour, enabling decentralized testing outside traditional laboratories.^[109]^[110] These systems typically rely on cartridge-based or microfluidic formats to minimize user intervention and contamination risks, with turnaround times reduced from days in centralized labs to 20-60 minutes.^[111]^[112] The GeneXpert system, developed by Cepheid, exemplifies early POC integration through its automated nucleic acid amplification testing (NAAT) cartridges, which process unprocessed samples in approximately 90 minutes.^[113] Endorsed by the World Health Organization in December 2010 following rigorous evaluation, it demonstrated high sensitivity and specificity for rapid pathogen detection, paving the way for broader adoption in resource-limited settings.^[114]^[115] Portable variants, such as the GeneXpert Omni introduced in 2015, further decentralize testing with battery-operated, handheld designs weighing under 2 kg, supporting field deployment.^[116] Handheld PCR devices, including compact thermocyclers like those from Ubiquitome or Axxin, enable isothermal or real-time amplification in mobile environments, often with fluorescence detection for multiplex targets.^[117]^[118] While next-generation sequencing (NGS) remains largely centralized due to computational demands, hybrid POC-NGS synergies are emerging, combining rapid PCR enrichment with portable sequencing modules for targeted genomic analysis.^[119] Integrated systems, such as the Dragonfly platform validated in 2025, incorporate power-free nucleic acid extraction in under 5 minutes followed by colorimetric detection, achieving lab-equivalent accuracy in field conditions.^[110] By 2025, POC molecular diagnostics have expanded beyond respiratory applications to non-respiratory nucleic acid testing (NAT), with Roche securing FDA clearance in early 2025 for broader syndromic panels.^[120] This evolution has empirically shortened diagnostic timelines, facilitating timely interventions during outbreaks and reducing empirical treatment durations.^[121] Real-world deployments show improved clinical management and resource allocation, though per-test costs remain 2-5 times higher than batch-processed lab assays due to single-use cartridges and device amortization.^[122]^[123] Cost-effectiveness analyses indicate net savings in high-burden scenarios through avoided hospitalizations, but scalability challenges persist in low-volume settings.^[122]

Applications in Infectious Diseases

Pathogen Identification and Outbreak Response

Molecular diagnostics enable rapid identification of infectious pathogens through techniques such as multiplex polymerase chain reaction (PCR) panels, which simultaneously detect multiple respiratory viruses including influenza, respiratory syncytial virus, and human metapneumovirus, often within hours of sample collection.^[124] These panels, exemplified by the FilmArray Respiratory Panel, have demonstrated increased diagnostic yield by 30% to 50% compared to traditional methods like direct fluorescent antibody testing, facilitating targeted antiviral therapy and reducing unnecessary antibiotic use.^[124] For unidentified agents, metagenomic next-generation sequencing (mNGS) sequences all nucleic acids in a sample without prior knowledge of the pathogen, proving instrumental in characterizing novel viruses.^[125] During the 2020 emergence of SARS-CoV-2, mNGS applied to nasopharyngeal swabs identified the virus without targeted enrichment, enabling genomic surveillance and variant tracking that informed global containment strategies.^[126] This approach detected co-infections and zoonotic elements, providing causal insights into transmission dynamics beyond initial PCR limitations.^[127] In the 2014-2016 West Africa Ebola outbreak, deployment of GeneXpert PCR systems in mobile laboratories in Liberia accelerated confirmation of Ebola virus disease cases from days to under 2 hours, enhancing contact tracing and isolation to curb exponential spread.^[128] Such rapid molecular confirmation correlated with improved outbreak response metrics, including reduced secondary transmission rates in equipped sites compared to areas reliant on slower serological methods.^[129] Despite these advances, molecular diagnostics face challenges with false negatives, particularly when viral variants harbor mutations in PCR primer-binding sites, as observed in SARS-CoV-2 lineages like B.1.617, which evaded certain assays and contributed to undetected community spread per surveillance data.^[130] Ongoing monitoring reveals that up to 10-20% of variant-specific discrepancies arise from such target failures, necessitating assay updates and complementary sequencing for comprehensive outbreak vigilance.^[131]

Antimicrobial Resistance Profiling

Antimicrobial resistance profiling in molecular diagnostics primarily involves genotypic methods that detect genetic determinants of resistance, such as mutations or acquired genes, directly from clinical samples or isolates, in contrast to phenotypic approaches that rely on culture-based growth inhibition assays to observe expressed resistance.^[132] These genotypic techniques enable rapid identification of resistance markers without requiring bacterial viability or extended incubation, addressing the limitations of phenotypic testing, which typically requires 24-48 hours or more for results.^[133] Polymerase chain reaction (PCR)-based assays target specific resistance genes, exemplified by detection of the mecA gene encoding penicillin-binding protein 2a in methicillin-resistant Staphylococcus aureus (MRSA), achieving sensitivities of 97-100% and specificities of 98-100% compared to culture confirmation.^[134] Next-generation sequencing (NGS), including targeted panels, profiles multi-drug resistance by sequencing multiple loci associated with resistance to various antibiotics, as demonstrated in tuberculosis diagnostics where targeted NGS detects mutations across drug classes with high sensitivity and specificity directly from sputum.00263-9/fulltext) Commercial platforms like multiplex PCR or NGS workflows have been validated for bloodstream infections, identifying resistance in Gram-positive and Gram-negative pathogens within hours.^[132] Genotypic profiling offers empirical advantages in speed—yielding results in 1-6 hours versus days for phenotypic methods—facilitating antimicrobial stewardship by enabling targeted therapy and reducing broad-spectrum antibiotic misuse, with clinical trials showing decreased time to effective treatment and lower mortality in sepsis cases.^[135] For instance, integration of rapid genotypic tests in hospital protocols has correlated with optimized prescribing and reduced resistance emergence in prospective studies.^[136] Despite these benefits, genotypic methods face limitations due to phenotype-genotype discordance, where detected genetic markers do not always translate to phenotypic resistance owing to factors like gene expression regulation, silent mutations, or novel/uncharacterized mechanisms not covered in assay panels.^[137] Studies report discordance rates of 5-20% in clinical isolates, necessitating confirmatory phenotypic testing for critical cases to avoid over- or under-treatment.^[138] Ongoing challenges include incomplete knowledge of resistance determinants and the need for updated databases to minimize false predictions.^[132]

Applications in Oncology

Tumor Profiling and Biomarker Discovery

Tumor profiling employs next-generation sequencing (NGS) panels or comprehensive genomic profiling to detect somatic mutations, gene fusions, copy number variations, and other alterations in tumor DNA, guiding precision oncology by matching patients to targeted therapies or immunotherapies. In non-small cell lung cancer (NSCLC), multigene panels routinely assay hotspots in EGFR and rearrangements in ALK, with EGFR exon 19 deletions or L858R mutations occurring in 10-50% of cases depending on ethnicity and ALK fusions in 3-7%.^[139]^[140] These alterations, validated through large-scale sequencing of tumor cohorts, enable selection for tyrosine kinase inhibitors (TKIs); for instance, the phase III FLAURA trial showed first-line osimertinib yielded a median progression-free survival (PFS) of 18.9 months in EGFR-mutated advanced NSCLC versus 10.2 months for comparator TKIs like gefitinib or erlotinib.^[141] ALK inhibitors such as crizotinib similarly improved PFS to 10.9 months versus 7.0 months with chemotherapy in ALK-positive NSCLC, as demonstrated in the PROFILE 1014 trial.^[142] Biomarker discovery leverages tumor profiling data from NGS to identify recurrent, functionally impactful alterations across patient cohorts, prioritizing those with causal roles in oncogenesis over mere associations. Microsatellite instability-high (MSI-H) status, arising from mismatch repair deficiency (dMMR), exemplifies a pan-tumor biomarker uncovered via profiling; MSI-H tumors exhibit hypermutation and predict response to PD-1 inhibitors, with pembrolizumab approval by the FDA in 2017 for any MSI-H/dMMR solid tumor based on objective response rates exceeding 40% in KEYNOTE-158.^[143] European Society for Medical Oncology guidelines endorse immunohistochemistry for MMR proteins or PCR for MSI as initial screening, followed by NGS confirmation, due to their prognostic and predictive value independent of tumor type.^[143] Such discoveries stem from empirical analysis of thousands of sequenced tumors, revealing MSI-H in 15% of colorectal cancers and rarer frequencies elsewhere.^[144] Despite advances, distinguishing actionable drivers from passenger mutations remains challenging, as computational predictions often overestimate causality without orthogonal validation like preclinical models or randomized trials. Many profiling-identified variants lack direct evidence of transforming potential, leading to potential mismatches in therapy assignment; for example, while EGFR and ALK alterations show robust PFS benefits, broader "actionable" calls in databases require scrutiny, as only a subset demonstrate consistent oncogenicity across functional assays.^[145] Tumor profiling thus prioritizes biomarkers with level 1 evidence from prospective studies, avoiding overreliance on correlative data from observational cohorts.^[146]

Liquid Biopsies for Monitoring

Liquid biopsies enable non-invasive monitoring of cancer progression through the analysis of circulating tumor DNA (ctDNA) in peripheral blood, particularly for detecting minimal residual disease (MRD) following curative-intent treatments such as surgery or chemotherapy in solid tumors.^[147] ctDNA, derived from apoptotic or necrotic tumor cells, reflects tumor genomic alterations and can quantify disease burden dynamically, offering a surrogate for tissue biopsies that are often infeasible post-treatment.^[148] Longitudinal ctDNA assessment correlates with relapse risk, with persistent detection post-therapy indicating occult micrometastases.^[149] In clinical practice, ctDNA-based MRD testing has demonstrated prognostic utility across tumor types, predicting recurrence earlier than standard imaging modalities; for instance, in non-small cell lung cancer, residual ctDNA after adjuvant therapy forecasts relapse with a hazard ratio exceeding 10, often months ahead of radiographic detection.^[149] Similarly, in breast cancer, post-neoadjuvant ctDNA positivity increases distant relapse risk by up to 36-fold.^[150] FDA-cleared assays like Guardant360 CDx, approved in August 2020 for comprehensive genomic profiling in advanced solid malignancies, provide foundational data for personalized ctDNA tracking panels, though no ctDNA test has full FDA approval specifically for MRD monitoring as of 2025.^[151]^[152] Advances reported in 2024 include refined tumor-informed sequencing approaches that enhance ctDNA detection limits to below 0.01% variant allele frequency, facilitating earlier relapse identification in colorectal and lung cancers compared to prior methods.^[153]^[154] However, sensitivity for MRD detection falls below 70% in tumors with low ctDNA shedding, such as pancreatic or brain cancers, due to biological heterogeneity and analytical constraints like clonal hematopoiesis interference.^[155]^[156] While ctDNA dynamics causally link to tumor burden via direct shedding from viable cells, positive findings do not invariably yield actionable interventions, as early detection may precede viable therapeutic windows without evidence of survival benefit from preemptive treatments in prospective trials.^[157]^[158]

Applications in Genetic and Reproductive Medicine

Inherited Disorder Screening

Inherited disorder screening in molecular diagnostics involves targeted genetic testing to detect heterozygous carriers of pathogenic variants in genes associated with autosomal recessive conditions, enabling informed reproductive decisions. Techniques such as polymerase chain reaction (PCR) for specific mutations and next-generation sequencing (NGS) for broader panels identify variants in germline DNA from blood or saliva samples.^[159] This approach focuses on monogenic disorders, where a single gene mutation causes disease upon inheritance of two copies, contrasting with polygenic risks that involve multiple variants with additive, lower-penetrance effects modulated by environment.^[160] Carrier screening programs originated with enzyme assays but shifted to molecular methods for higher accuracy; for instance, hexosaminidase A activity testing evolved to direct HEXA gene sequencing for Tay-Sachs disease. In Ashkenazi Jewish populations, where carrier frequency reaches 1 in 27, widespread screening since the 1970s has reduced Tay-Sachs births by over 90%, from approximately 50-100 annual U.S. cases pre-screening to fewer than 10 by 2000, primarily through preimplantation genetic diagnosis or pregnancy termination after counseling.^[161]^[162] Similarly, cystic fibrosis (CF) screening targeting CFTR gene variants, with carrier rates of 1 in 25-30 in Caucasian populations, correlated with a decline in CF birth incidence; in one Italian study, areas with screening saw birth prevalence drop from 1 in 2,500 to lower rates post-implementation.^[163] In Israel, population-wide CF carrier screening reduced affected births by over 90% since 2002, shifting surviving cases toward milder genotypes.^[164] Expanded carrier screening (ECS) panels now interrogate 100-500 genes for dozens of recessive disorders, using NGS to detect variants beyond ethnicity-specific risks, though residual carrier risks persist due to incomplete variant catalogs.^[165] These panels prioritize conditions with high carrier frequencies, severe phenotypes, and available interventions, but empirical validation remains tied to monogenic causality rather than polygenic scores, which lack comparable predictive power for actionable screening due to their continuum of risk without discrete thresholds.^[166] Population-level data confirm ECS feasibility, yet uptake varies, with programs like those in Israel demonstrating sustained incidence reductions only where counseling integrates molecular results with empirical outcomes.^[167]

Prenatal and Carrier Testing

Noninvasive prenatal testing (NIPT) utilizes cell-free fetal DNA (cfDNA) from maternal plasma to detect common fetal aneuploidies, such as trisomies 21, 18, and 13, without the risks associated with invasive procedures like amniocentesis.^[168] Commercial NIPT was first introduced in 2011, marking a shift toward higher-accuracy screening with sensitivity exceeding 99% and specificity near 99% for trisomy 21 in high-risk pregnancies.^[169]^[170] These tests analyze fetal DNA fractions as low as 4%, employing methods like massively parallel sequencing to quantify chromosomal representations, though positive predictive values can vary (e.g., 80.9% for trisomy 21 in some validations due to confined placental mosaicism).^[171] Carrier testing employs targeted molecular panels or next-generation sequencing to identify heterozygous mutations in genes associated with autosomal recessive disorders, such as cystic fibrosis (CFTR gene) or spinal muscular atrophy (SMN1 gene), typically preconception or early in pregnancy.^[172] For cystic fibrosis, detection rates reach 88-98% in non-Hispanic Caucasian populations using expanded mutation panels, though rates drop to 64-72% in African-American or Hispanic groups due to ethnic variability in mutation spectra.^[173] These screens inform reproductive risks, with residual carrier frequencies around 1/25-1/60 across populations, enabling options like donor gametes or preimplantation genetic testing.^[174] In assisted reproduction, preimplantation genetic testing for monogenic disorders (PGT-M) sequences biopsied blastocysts to exclude those carrying two pathogenic variants from carrier parents, directly averting disease transmission with near-100% specificity for known mutations.^[172] Preimplantation genetic testing for aneuploidy (PGT-A), however, aims to select euploid embryos to boost implantation but yields mixed empirical outcomes; randomized controlled trials show no overall increase in live birth rates per initiated cycle compared to morphological selection, with some demonstrating reductions (e.g., 26% vs. 38% ongoing pregnancy rates).^[175]^[176] Meta-analyses confirm this lack of benefit in unselected IVF patients, attributing potential biases to embryo biopsy artifacts or self-fulfilling mosaicism, though subgroup data in advanced maternal age hint at modest gains without statistical significance in large trials.^[177] Such testing facilitates parental selection of embryos based on genetic profiles, supported by verifiable risk reductions for targeted conditions.

Therapeutic Guidance and Monitoring

Pharmacogenomics and Personalized Dosing

Pharmacogenomics applies molecular diagnostic techniques to identify genetic variants influencing drug metabolism, transport, and target response, enabling tailored dosing to optimize efficacy and minimize toxicity. Key variants in cytochrome P450 enzymes, such as CYP2D6 and CYP2C9, alter enzymatic activity, directly impacting pharmacokinetic profiles; for instance, reduced CYP2D6 function impairs prodrug activation, while variants in VKORC1 modulate anticoagulant sensitivity by affecting vitamin K epoxide reductase, the warfarin target.^[178]^[179]^[180] A prominent FDA-labeled example involves codeine, where CYP2D6 genotypes predict conversion to active morphine: ultra-rapid metabolizers (e.g., duplicated alleles) exhibit excessive morphine production, risking respiratory depression and death, prompting FDA contraindications for such patients and breastfeeding mothers with normal metabolism due to milk transfer risks.^[181]^[179] Poor metabolizers, conversely, experience inadequate analgesia from reduced activation, highlighting how genotype causally links to metabolic flux but not invariably to downstream efficacy if alternative pathways compensate. For warfarin, FDA labeling incorporates CYP2C9 and VKORC1 genotyping for initial dosing algorithms, as CYP2C9 variants (e.g., *2, *3) decrease clearance, elevating bleeding risk, while VKORC1 -1639G>A reduces required doses by up to 30% in variant carriers; Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend genotype-adjusted starts to achieve therapeutic INR faster.^[178]^[182]^[183] Empirical studies demonstrate pharmacogenomic-guided dosing reduces adverse drug reactions (ADRs) by 20-30% in targeted populations, as seen in prospective trials where multi-gene panels adjusted prescriptions, lowering hospitalization-linked events compared to standard care.^[184]^[185]^[186] However, broad adoption remains limited, with evidence gaps persisting for many drugs where variants predict metabolism but fail to correlate with clinical outcomes due to polygenic influences, environmental modulators like diet or comorbidities, and incomplete penetrance.^[187]^[188] Barriers include insufficient prospective randomized data beyond select biomarkers, clinician knowledge deficits, and inconsistent payer reimbursement, despite CPIC endorsements for high-evidence pairs.^[189]^[190]

Disease Progression and Treatment Response Tracking

Circulating tumor DNA (ctDNA) serves as a key biomarker in molecular diagnostics for tracking cancer progression and response to therapy, offering a non-invasive means to quantify tumor burden over time through serial plasma sampling. Levels of ctDNA typically decline with effective treatment and rise with disease advancement, enabling earlier detection than traditional imaging in some cases. For instance, ctDNA dynamics have been shown to correlate with MRI-assessed tumor response in solid tumors, where weekly monitoring reveals changes preceding radiological shifts by weeks.^[191] In immunotherapy contexts, ctDNA clearance post-treatment initiation predicts favorable outcomes; a 2023 study in non-small cell lung cancer patients treated with pembrolizumab found that individuals achieving undetectable ctDNA despite stable disease on imaging exhibited prolonged progression-free survival compared to those with persistent ctDNA. Aggregate analyses from 2020s clinical trials further demonstrate ctDNA's prognostic utility, such as rapid clearance within 10 weeks of therapy associating with improved overall and progression-free survival in advanced non-small cell lung cancer.^[192]^[193] For hematologic malignancies like acute myeloid leukemia, molecular assessment of minimal residual disease (MRD) via techniques such as quantitative PCR or next-generation sequencing detects leukemic clones persisting after remission induction, providing independent prognostic value for relapse and survival. A 2018 multicenter trial reported that molecular MRD positivity during morphologic complete remission conferred a hazard ratio of 5.56 for relapse, with 82% of MRD-positive patients relapsing versus 32% of MRD-negative ones. Updates from 2021 emphasize MRD's role in risk stratification, guiding decisions on consolidation therapy intensity.^[194]^[195] These approaches necessitate repeated testing to capture dynamic biomarker fluctuations, as single measurements may not fully reflect ongoing disease states; persistent or emerging mutations in ctDNA or MRD can signal emerging resistance, prompting therapeutic adjustments.^[154]

Limitations and Technical Challenges

Sensitivity, Specificity, and Error Rates

In molecular diagnostics, sensitivity measures the proportion of true positives correctly identified, while specificity quantifies true negatives correctly detected; error rates encompass false positives (due to contamination or cross-reactivity) and false negatives (from low analyte levels or sampling variability).^[196] Polymerase chain reaction (PCR) assays typically achieve sensitivities of 80-95% and specificities exceeding 95% in controlled settings, though real-world performance varies by target and sample type; for instance, multiplex PCR for infectious agents yields pooled sensitivity of 80% (95% CI: 73-86%) and specificity of 83% (95% CI: 77-88%).^[197] Contamination risks elevate false positive rates in PCR, potentially reaching 1-5% without stringent controls, as amplicon carryover amplifies non-target signals.^[198] Next-generation sequencing (NGS) variant calling exhibits error rates of 0.1-1% per base, with false positive indel calls comprising up to 5% in complex genomic regions due to alignment artifacts and sequencing biases.^[199] ^[200] In clinical applications, NGS sensitivity for low-frequency variants drops below 90% when allele fractions fall under 5%, constrained by inherent platform error rates of 0.1-1%.^[199] Empirical data from SARS-CoV-2 PCR testing (2020-2022) illustrate these limitations: meta-analyses report initial false negative rates up to 58% in confirmed cases, driven by timing of sample collection relative to viral load peaks, with overall detection rates averaging 83% within 14 days post-symptom onset.^[201] ^[202] False positives remained low (<1%) in high-specificity assays but amplified in low-prevalence screening, underscoring prevalence-dependent positive predictive value.^[203] Beyond technical artifacts, biological heterogeneity—such as tumor clonal diversity or genetic mosaicism—causally contributes to errors by introducing sampling biases that evade uniform detection; for example, intratumoral heterogeneity reduces effective sensitivity in oncology profiling by 10-30% for minor subpopulations.^[204] ^[205] This underscores that diagnostic accuracy hinges on both assay fidelity and the inherent variability of biological targets, rather than instrumentation alone.^[206]

Cost, Accessibility, and Infrastructure Demands

The costs of next-generation sequencing (NGS) tests in molecular diagnostics typically range from $500 to $2,000 per sample, depending on panel complexity, throughput, and laboratory overhead, reflecting substantial investments in reagent development, bioinformatics pipelines, and regulatory validation.^[28]^[207] Point-of-care (POC) molecular assays, such as cartridge-based PCR systems, incur per-test expenses exceeding $100 in non-subsidized settings, though economies of scale and volume procurement can reduce this for specific applications like infectious disease detection.^[208] These pricing structures stem from the capital-intensive nature of innovation, including clinical trials and quality assurance, which ensure reliability but limit scalability without technological maturation.^[209] Accessibility remains constrained in low- and middle-income countries (LMICs), where empirical studies document uptake rates below 20% for advanced molecular tests due to fragmented supply chains and dependency on imported reagents prone to spoilage without cold storage.^[210] Infrastructure demands exacerbate these barriers, including reliable electricity for thermocyclers and sequencers—often unavailable in rural facilities—and the need for biosafety level 2 labs with trained technicians, leading to error rates up to 15% higher in under-resourced environments compared to high-income settings.^[211]^[212] Global market projections anticipate growth to approximately $30 billion by 2035, driven by automation and multiplexing, yet this expansion disproportionately benefits urban centers, with LMICs representing less than 10% of current deployment.^[213]^[33] High costs accurately capture the empirical realities of R&D amortization, as evidenced by the 99% decline in per-base sequencing expenses since 2001, without evidence of systemic overpricing beyond competitive margins.^[214] Government subsidies in some markets, while intended to boost adoption, have occasionally distorted allocation by prioritizing politically favored technologies over cost-effective alternatives, as seen in variable reimbursement models that inflate demand for unproven assays.^[215] This dynamic underscores the need for market-driven incentives to sustain innovation, rather than interventions that may hinder long-term efficiency.^[216]

Criticisms and Empirical Shortcomings

Overreliance and Clinical Misinterpretation

In next-generation sequencing (NGS) for molecular diagnostics, variants of uncertain significance (VUS) frequently complicate clinical interpretation, as these genetic changes lack established links to disease causality, leading to diagnostic uncertainty and potential overreliance on inconclusive results.^[217] Studies indicate that VUS constitute a substantial portion of NGS outputs, with up to 20-40% of variants in cancer panels remaining unclassified, prompting clinicians to withhold or alter treatments despite insufficient evidence of pathogenicity.^[218] This uncertainty arises because VUS classification relies on evolving databases and predictive models that often fail to distinguish benign polymorphisms from true drivers, fostering interpretive pitfalls where associative correlations are mistaken for causal mechanisms.^[219] Incidental findings, unrelated to the primary diagnostic indication, further exacerbate misinterpretation risks, occurring in approximately 3% of large-scale genomic tests such as those in the eMERGE network involving over 21,000 participants.^[220] These findings, often involving actionable genes outside the test scope, can lead to unnecessary follow-up interventions; for instance, secondary variants in hereditary cancer genes appear in 1-5% of exome sequences, but their causal role versus mere association remains unproven without functional validation.^[220] Empirical data highlight that distinguishing causal variants requires orthogonal evidence like segregation studies or in vitro assays, yet clinical practice frequently overinterprets associative signals from population databases, inflating perceived risks.^[221] Overreliance manifests in screening contexts, such as prostate cancer genomics, where molecular markers contribute to overdiagnosis rates of 23-42% among screen-detected cases, identifying indolent lesions unlikely to progress without intervention.^[222] Polygenic risk scores, intended to refine risk stratification, may instead amplify this issue by conflating statistical associations with deterministic causality, leading to escalated biopsies and treatments for low-risk individuals.^[223] In precision medicine applications for common diseases like prostate cancer, promises of tailored outcomes remain largely unfulfilled, as genomic classifiers explain only a fraction of variance in progression and fail to outperform traditional clinico-pathologic factors in prospective validation for most patients.^[224] Conflicting variant interpretations, reported in 5.7% of rare disease cases, underscore systemic challenges in achieving consensus on pathogenicity, often resulting from inconsistent application of guidelines like those from the American College of Medical Genetics.^[221]^[225]

Hype Versus Proven Outcomes in Precision Medicine

Prominent advocates and funding bodies post-2010 promoted precision medicine as a paradigm shift, forecasting that molecular diagnostics would enable routine genomic profiling to match therapies to individual tumor profiles, thereby revolutionizing cancer treatment and extending survival across diverse malignancies.^[226] This narrative, often termed the "genomic revolution," was bolstered by early successes in niche cases, such as EGFR inhibitors in non-small cell lung cancer, and fueled substantial investments exceeding $4 billion annually in the U.S. by 2015 for sequencing and companion diagnostics.^[227] However, large-scale empirical assessments from randomized trials reveal that such benefits remain confined to rare, mutation-specific contexts, with broad applicability undermined by tumor heterogeneity and limited actionable targets. In precision oncology, targeted therapies informed by molecular diagnostics yield meaningful clinical responses in fewer than 10% of patients when applied pan-cancer, as most tumors lack driver alterations responsive to approved agents; for example, comprehensive profiling identifies potentially actionable mutations in 20-40% of advanced cases, but confirmed progression-free survival gains occur in under 10%, per analyses of real-world cohorts and basket trials like NCI-MATCH.^[228] Randomized evidence further tempers enthusiasm: while select trials demonstrate hazard ratios for overall survival as low as 0.6 in mutation-enriched subgroups (e.g., BRAF inhibitors in melanoma), umbrella and platform studies across solid tumors show no population-level survival advantage, with response rates averaging 10-20% and frequent resistance development within months.^[229] These outcomes contrast with promotional claims, highlighting that precision approaches excel in predefined subsets—such as 10-15% of lung cancers with ALK fusions—but fail to transform heterogeneous diseases like pancreatic or glioblastoma, where <5% derive benefit.^[230] Beyond oncology, polygenic risk scores derived from molecular diagnostics exhibit weak predictive power for common diseases, typically explaining less than 5-10% of trait variance in validation cohorts; for coronary artery disease, top-performing scores reclassify risk for only 1-3% of individuals beyond clinical factors, limiting utility to auxiliary stratification rather than standalone guidance.^[231] Empirical evaluations in population screening underscore this shortfall, with scores failing to outperform traditional models in prospective prediction and often yielding area under the curve values below 0.65 for binary outcomes.^[232] Post-2010 cancer survival trends reflect this disparity: U.S. age-adjusted 5-year rates rose modestly from 66.3% (2004-2010) to 67.7% (2013-2019), driven primarily by immunotherapy and early detection rather than widespread molecular matching, which contributes marginally outside specialized indications.^[233] Such discrepancies arise partly from market dynamics, where pharmaceutical entities emphasize anecdotal successes and off-label expansions to justify high costs—averaging $150,000 per precision drug course—despite randomized data indicating equivalent or inferior outcomes to standard care in non-selected populations.^[234] Truth-seeking scrutiny of trial registries reveals over 80% of precision oncology studies as single-arm or non-randomized by 2020, inflating perceived efficacy while underrepresenting null results from rigorous designs.^[229] Consequently, while molecular diagnostics enable validated niches, the empirical record cautions against equating technological feasibility with therapeutic universality, prioritizing causal evidence over correlative associations in assessing impact.^[235]

Ethical, Legal, and Societal Considerations

Molecular diagnostics, particularly through direct-to-consumer (DTC) genetic testing and large-scale genomic sequencing, generate vast personal data sets that heighten privacy risks via cyberattacks and unauthorized access. In October 2023, DTC provider 23andMe suffered a breach exposing ancestry and health reports of nearly 7 million users, including genetic relatives of 6.9 million, due to credential-stuffing attacks exploiting weak authentication.^[236] Subsequent investigations revealed inadequate security measures, leading to a £2.31 million fine in June 2025 by the UK Information Commissioner's Office for failing to protect UK users' data.^[237] Such incidents underscore empirical vulnerabilities in storing sensitive genetic information, where breaches can enable identity theft, familial tracing, or commercial exploitation without robust encryption or anonymization.^[238] Informed consent in molecular diagnostics faces challenges from the volume and unpredictability of results, especially incidental findings—genetic variants unrelated to the primary diagnostic query but indicative of unrelated risks. Clinical sequencing often yields such discoveries, complicating pre-test consent as patients may not anticipate or comprehend psychological, familial, or actionable implications.^[239] The American College of Medical Genetics and Genomics recommends reporting certain actionable incidental variants, yet obtaining truly informed consent requires detailing potential for variants of uncertain significance (VUS) or non-actionable findings, which can overwhelm comprehension and lead to post-hoc regret or disputes.^[240] Empirical studies highlight that patients receiving copious genomic data struggle to provide granular consent, raising ethical tensions between autonomy and the duty to disclose clinically significant results.^[241] Genetic discrimination risks prompted the U.S. Genetic Information Nondiscrimination Act (GINA) of 2008, which prohibits health insurers from denying coverage or adjusting premiums based on genetic information and bars employers from using it in hiring, firing, or compensation decisions.^[242] Pre-GINA, anecdotal cases included life insurers denying policies to asymptomatic carriers of Huntington's disease mutations or BRCA1 variants, fueling legislative action amid fears of adverse selection.^[243] However, GINA's limitations exclude life, disability, and long-term care insurance, leaving gaps where empirical post-enactment discrimination persists in non-health sectors.^[242] Surveys post-GINA indicate low verified incidents in covered areas—despite persistent public fears deterring testing uptake—but underscore that privacy breaches pose more immediate causal threats than rare discriminatory acts, favoring individual risk assessment over blanket prohibitions.^[244]^[243]

Equity, Regulation, and Innovation Barriers

Disparities in molecular diagnostics equity arise primarily from the underrepresentation of non-European ancestry groups in genomic databases, which limits the applicability of diagnostic tools across diverse populations. For instance, public genomic databases contain genetic data that is disproportionately derived from individuals of European descent, with non-European groups comprising less than 20% of samples in major repositories as of 2018, leading to reduced accuracy in variant interpretation and higher error rates for underrepresented populations in clinical applications like cancer genomics or infectious disease testing. This underrepresentation persists due to historical sampling biases in research cohorts, resulting in missed gene-disease associations specific to African, Asian, or Indigenous ancestries, which empirically exacerbates health outcome gaps rather than innate biological differences. Market-driven efforts to expand diverse datasets through private initiatives have shown promise in improving diagnostic equity by incentivizing broader data collection, whereas redistributive policies mandating inclusion quotas often fail to address root causes like low participation rates tied to trust deficits in biased institutions. Regulatory hurdles, particularly overreach in oversight of laboratory-developed tests (LDTs), impose significant barriers to innovation and timely access. The U.S. Food and Drug Administration's (FDA) 2024 final rule classifying LDTs as medical devices subject to premarket review and quality system requirements has sparked controversies over anticipated delays in test development and escalated compliance costs, potentially restricting availability of specialized molecular diagnostics for rare diseases or companion diagnostics. Critics, including hospital associations, argue this regulatory expansion exceeds statutory authority and burdens smaller labs, which develop over 80% of LDTs, thereby slowing innovation compared to pre-rule flexibility that enabled rapid deployment during public health crises. In Europe, the In Vitro Diagnostic Regulation (IVDR), implemented progressively since 2017 with full enforcement by 2027, enforces even stricter conformity assessments and notified body requirements, leading to certification backlogs that have delayed market entry for molecular assays by up to 24 months in some cases, contrasting with faster U.S. adoption rates for similar technologies prior to tightened LDT rules. These regulatory frameworks disproportionately hinder point-of-care (POC) molecular diagnostics in developing regions, where infrastructure limitations compound approval delays and high validation costs. In low- and middle-income countries (LMICs), stringent international standards adapted from high-income regulators like the FDA or EU often overlook local adaptation needs, resulting in underutilization of POC platforms for tuberculosis or HIV monitoring despite proven efficacy in trials; for example, regulatory misalignment has stalled deployment of near-POC devices in Level 2 facilities, where only 10-20% of potential sites achieve compliance due to economic and bureaucratic barriers. Empirical comparisons indicate that less regulated markets foster quicker POC innovation and price reductions through competition, as seen in voluntary scaling of multiplex PCR tests in Asia-Pacific regions, outperforming subsidized redistribution models that sustain high costs without proportional access gains. Over-regulation thus causally perpetuates inequities by prioritizing uniformity over adaptive, market-led solutions that historically drive broader availability via cost-lowering economies of scale.

References

[1]
Definition of molecular diagnostics - NCI Dictionary of Cancer Terms
Laboratory methods that are used to help identify a disease or the risk of developing a disease, such as cancer, by studying molecules, such as DNA, RNA, and ...
[2]
Molecular Diagnostics - an overview | ScienceDirect Topics
Molecular diagnostics is defined as the analysis of genetic changes in patient samples, utilizing various modalities to assess different types of target ...
[3]
Molecular diagnostic techniques - PMC - PubMed Central - NIH
A range of methods such as culture, electron microscopy, and pathogen genome detection by polymerase chain reaction (PCR) are used.
[4]
Molecular Diagnostics: Techniques, Applications & Testing
Molecular diagnostic techniques are used in clinical analysis to detect and analyze genetic material, such as DNA and RNA, to diagnosis and monitor diseases.
[5]
Modern Methods of Molecular Diagnostics - ScienceDirect.com
Apr 25, 2024 · Modern molecular diagnostics use techniques like quantitative PCR, DNA melting analysis, digital PCR, and massive parallel sequencing, ...
[6]
Molecular diagnostics: A historical perspective - ScienceDirect.com
A major milestone in the early 1990s was the transition of the polymerase chain reaction (PCR) from the research laboratory to the clinical laboratory. Many ...
[7]
Forty Years of Molecular Diagnostics for Infectious Diseases
Jul 19, 2022 · Nearly 40 years have elapsed since the invention of the PCR, with its extremely sensitive and specific ability to detect nucleic acids via in vitro enzyme- ...
[8]
Current applications and future trends of molecular diagnostics ... - NIH
Molecular diagnostics of infectious diseases, in particular, nucleic-acid-based methods, are the fastest growing field in clinical laboratory diagnostics.
[9]
Embracing High-Impact Applications of Molecular Diagnostics
Molecular methods can be used to identify infectious agents and diagnose infectious disease. They are key factors in diagnosis and workup of cancers and are ...
[10]
Molecular Diagnostics Research That Could Transform Healthcare ...
Jan 3, 2024 · Lab experts use molecular diagnostic methods to identify genetic markers that affect drug metabolism and efficacy—information that providers ...
[11]
the past, present, and future of molecular diagnostics - PMC - NIH
As molecular diagnostics has evolved, it has demonstrated clear advantages over some traditional methods, although it does not completely replace other methods.
[12]
A Structure for Deoxyribose Nucleic Acid - Nature
The determination in 1953 of the structure of deoxyribonucleic acid (DNA), with its two entwined helices and paired organic bases, was a tour de force in ...
[13]
The Discovery of the Double Helix, 1951-1953 | Francis Crick
The discovery in 1953 of the double helix, the twisted-ladder structure of deoxyribonucleic acid (DNA), by James Watson and Francis Crick marked a milestone ...
[14]
Hamilton O. Smith – Facts - NobelPrize.org
Using a purified restriction enzyme taken from a bacterium, in 1970, Smith was able to show that the restriction enzyme cleaves the DNA molecule in the middle ...
[15]
How restriction enzymes became the workhorses of molecular biology
A significant breakthrough came in 1970 when the first of two papers from Smith's laboratory described an enzyme, endonuclease R, that was able to cleave ...
[16]
The Characterization of Restriction Endonucleases - PubMed Central
The two JBC Classics reprinted here detail Smith's efforts to discover the rules governing sequence recognition in the Type II restriction endonuclease HhaII ...
[17]
1972: First Recombinant DNA
Apr 26, 2013 · The first production of recombinant DNA molecules, using restriction enzymes, occurred in the early 1970s.Missing: foundations diagnostics structure pre-
[18]
Herbert W. Boyer and Stanley N. Cohen | Science History Institute
By inventing recombinant-DNA technology, Boyer and Cohen jump-started the biotechnology industry, including Genentech, which creates important applications ...
[19]
Era of Molecular Diagnostics Techniques before and after the ...
Oct 11, 2022 · The simple and most common molecular diagnostic techniques used in the clinical laboratory were FISH, PCR, microarrays, MALDI-TOF, ELISA, and ...
[20]
Recombinant DNA | Summary - WhatisBiotechnology.org
Recombinant DNA is a form of DNA constructed in the laboratory. It is generated by transferring selected pieces of DNA from one organism to another.
[21]
Kary B. Mullis – Facts - NobelPrize.org
In 1985, Kary Mullis invented the process known as polymerase chain reaction (PCR), in which a small amount of DNA can be copied in large quantities over a ...
[22]
Use of the polymerase chain reaction for early detection of ... - PubMed
We used the polymerase chain reaction, a new technique that amplifies proviral sequences of HIV within DNA, to detect HIV infection in peripheral-blood ...Missing: first | Show results with:first
[23]
Evolution of Genetic Techniques: Past, Present, and Beyond - NIH
In this paper, a brief summary of genetic history with short explanations of most popular genetic techniques is given.
[24]
Sanger Sequencing - Embryo Project Encyclopedia
Aug 8, 2025 · Researchers working during the early 1980s used Sanger sequencing to produce new findings. In 1981, scientists used the Sanger technique to ...
[25]
DNA microarrays: Types, Applications and their future - PMC - NIH
In 1994, Fodor et.al. at the recently formed company of Affymetrix demonstrated the ability to use this technology to generate DNA arrays consisting of 256 ...
[26]
Molecular diagnostics: A historical perspective - ScienceDirect.com
In 1996, Abbott Diagnostics (Abbott Park, IL) received the first FDA ... Molecular genetics was also introduced to its first population screening program for ...
[27]
DNA Sequencing Costs: Data
May 16, 2023 · Data used to estimate the cost of sequencing the human genome over time since the Human Genome Project.
[28]
Cost of NGS | Comparisons and budget guidance - Illumina
Next-generation sequencing costs have decreased dramatically. Find resources to help you plan your experimental budget.Cost Of Ngs · With Decreasing Costs Thanks... · Evaluate Ngs Costs And Plan...Missing: timeline | Show results with:timeline
[29]
Innovation at Illumina: The road to the $600 human genome - Nature
Illumina's NGS has helped to revolutionize genomics research and has wide applications in fields such as infectious disease, oncology, genetic disease and ...
[30]
Biomarkers Compendium - NCCN
The NCCN Biomarkers Compendium contains information designed to support decision-making around the use of biomarker testing in patients with cancer.
[31]
Impact of Targeted Therapy on the Survival of Patients With ... - NIH
Progression-Free Survival and OS were superior in patients who received targeted therapy than those treated only with CHT, the 2 years rate of PFS and OS was ...
[32]
Molecular Diagnostic Testing: Healthy Outlook - DeciBio
The market size, estimated at $4.8 billion in 2010, has experienced a ~15+ percent growth rate over the last few years, driven by the increased availability of ...
[33]
Molecular Diagnostics Market Growth, Drivers, and Opportunities
Global molecular diagnostics market valued at $18.29B in 2024, reached $19.48B in 2025, and is projected to grow at a robust 9.6% CAGR, hitting $30.74B by ...
[34]
CDC Museum COVID-19 Timeline
February 5, 2020. CDC begins shipping its laboratory test kit to detect the SARS-CoV-2 virus, “CDC 2019-nCoV Real Time RT-PCR, ...
[35]
Testing at scale during the COVID-19 pandemic - Nature
May 4, 2021 · This Review describes the changing role of testing during the COVID-19 pandemic, including the use of genomic surveillance to track SARS-CoV-2 transmission ...Missing: timeline | Show results with:timeline
[36]
Roche receives FDA clearance with CLIA waiver for cobas® liat ...
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to aid in diagnosing sexually transmitted infections at the point of care. More ...
[37]
Molecular Target - an overview | ScienceDirect Topics
A specific molecular target is identified through an understanding of the cellular or molecular biology of a disease.
[38]
Epigenetic biomarkers: Current strategies and future challenges for ...
This research is showing the potential of epigenetic biomarkers to provide valuable information about disease diagnosis, prognosis, and treatment monitoring [19] ...
[39]
Molecular basis of epigenetic regulation in cancer diagnosis and ...
Aug 23, 2022 · Therefore, alterations in epigenetic marks may have clinical utility as potential biomarkers for early cancer detection and diagnosis. In this ...
[40]
Discovery – BRCA Connection to Breast and Ovarian Cancer - NCI
Mar 7, 2014 · NCI-funded research helped identify inherited BRCA1 and BRCA2 genetic mutations and their connection to breast and ovarian cancer.
[41]
Questions About the BRCA1 and BRCA2 Gene Study and Breast ...
Jun 1, 2012 · The first, BRCA1 (for BReast CAncer gene), was discovered in 1994, and the second, BRCA2, in 1995. The search for other genes continues.
[42]
Hereditary Cancer Genetic Testing: 30 Years of Impact on ... - NIH
Aug 28, 2024 · In 1994 the BRCA1 gene was discovered, and its counterpart BRCA2 would follow a year later. ... As we celebrate 30 years since this monumental ...
[43]
Principles and applications of polymerase chain reaction in medical ...
The aim of the present study is to outline the principles and applications of conventional PCR and Real-Time PCR techniques in some medical sciences.
[44]
What is PCR? - Roche Diagnostics
Polymerase chain reaction (PCR) is an efficient and cost-effective way to copy small specific DNA or RNA sequences.
[45]
28.2: Base Pairing in DNA - The Watson-Crick Model
Mar 20, 2024 · The thymine (T) base on one strand can form two H-bonds with an adenine (A) base on the other strand (this is called an AT base pair). Double- ...
[46]
Essentials of Real-Time PCR | Thermo Fisher Scientific - ES
Since the SYBR Green I dye binds to all double-stranded DNA, the result is an increase in fluorescence intensity proportionate to the amount of PCR product ...About Real-Time PCR (qPCR... · About Sequence Detection...
[47]
Real-Time PCR: Understanding Ct | Thermo Fisher Scientific - US
C t (threshold cycle) is the intersection between an amplification curve and a threshold line (Figure 1B). It is a relative measure of the concentration of ...Missing: mechanism | Show results with:mechanism
[48]
PCR-based diagnostics for infectious diseases: uses, limitations ...
Three of the most commonly encountered problems are (1) inadequate removal of PCR inhibitors in the sample, such as haemoglobin, blood culture media, urine, and ...
[49]
Differential susceptibility of PCR reactions to inhibitors
The presence of inhibitors has the potential to increase error, reduce assay resolution, and produce false results in both quantitative and qualitative PCR ...
[50]
The Discovery of PCR: ProCuRement of Divine Power - PMC - NIH
The origins of PCR are usually attributed to Kary Mullis, a technician at the Cetus Corporation, assigned to improve the synthesis of oligonucleotides. He ...
[51]
History of the Polymerase Chain Reaction Videohistory Collection ...
Kary Mullis invented the PCR technique in 1985 while working as a chemist at the Cetus Corporation, a biotechnology firm in Emeryville, California. The ...Collection Overview · Historical Note · Introduction · Descriptive Entry
[52]
Why is Real-time PCR is superior to end-point PCR? - Help Center
Real-time or quantitative PCR (qPCR) provides more consistent, reproducible results and is more sensitive than end-point PCR.
[53]
https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/genomics/qpcr/quantitative-pcr
[54]
Analytical and Clinical Evaluation of a TaqMan Real-Time PCR ...
Jun 5, 2023 · We found the in-house assay was highly sensitive, with a detection limit of 3.95 RNA copies/reaction. The analytical specificity of the assay ...
[55]
Methods to determine limit of detection and limit of quantification in ...
Here we present methods to determine the limit of detection (LoD) and the limit of quantification (LoQ) as applicable to qPCR.
[56]
An examination of the accuracy of a sequential PCR and ...
Feb 7, 2015 · The sensitivity of this PCR-only test was around 94%, providing a risk of false-negative results of c. 6% and a risk of false-positive results ...
[57]
Loop-mediated isothermal amplification of DNA - Oxford Academic
We have developed a novel method, termed loop-mediated isothermal amplification (LAMP), that amplifies DNA with high specificity, efficiency and rapidity ...Abstract · INTRODUCTION · RESULTS AND DISCUSSION
[58]
Advancements and applications of loop-mediated isothermal ...
Jul 16, 2024 · Loop-mediated isothermal amplification (LAMP) is a molecular diagnostic technology introduced by Notomi et al. (2000), enabling rapid nucleic ...
[59]
Comparative Diagnostic Performance of a Novel Reverse ...
The overall sensitivity and specificity values of HG COVID-19 RT-LAMP versus RT-PCR were 97.0% (95% CI: 93.6–98.9%) and 98.5% (95% CI: 95.7–99.7%), respectively ...
[60]
Comparative evaluation of PCR and loop-mediated isothermal ...
Oct 24, 2024 · However, LAMP demonstrated lower clinical specificity (94.74%) compared to PCR (100%) when 40 clinical samples were tested. None of the DNA ...
[61]
Impact of Proficiency Testing Program for Laboratories Conducting ...
Discordant values were attributed to transcriptional errors, post-PCR contamination, performance of the wrong test, and/or improper interpretation of results, ...Missing: risks | Show results with:risks
[62]
Digital PCR and Real-Time PCR (qPCR) Choices for Different ...
qPCR is suitable when the mutation frequency is known to be above 1%, and for high resolution melt analysis (HRM). Leading technology: dPCR. Detect mutation ...
[63]
a comparative analysis study of LAMP, conventional PCR, nested ...
Jun 22, 2020 · Conclusions. The analytical sensitivity comparison among the conventional PCR, nPCR, qPCR and LAMP reveals that the LAMP outperformed the others ...
[64]
Development of quantitative multiplex RT-qPCR one step assay for ...
Jul 26, 2023 · Analysis of the repeatability data revealed a Limit of Quantification of 5 copies/reaction and Limit of Detection (95%) of 2.83 copies per ...<|separator|>
[65]
Sanger Sequencing - an overview | ScienceDirect Topics
Sanger sequencing is a robust testing strategy able to determine whether a point mutation or small deletion/duplication is present. It has been widely used for ...
[66]
Guidelines for Sanger sequencing and molecular assay monitoring
Feb 18, 2020 · Genetic sequencing, or DNA sequencing, using the Sanger technique has become widely used in the veterinary diagnostic community.
[67]
What is Sanger sequencing? | Thermo Fisher Scientific - ES
However, Sanger sequencing is best suited for medium- to low-throughput targeted sequencing projects; higher-throughput DNA sequencing technologies based on ...
[68]
Human Genome Project Fact Sheet
Jun 13, 2024 · In 2003, the Human Genome Project produced a genome sequence that accounted for over 90% of the human genome. It was as close to complete as ...Missing: diagnostic | Show results with:diagnostic
[69]
The Human Genome Project: big science transforms biology and ...
Sep 13, 2013 · The Human Genome Project has transformed biology through its integrated big science approach to deciphering a reference human genome sequence.
[70]
Fluorescence In Situ Hybridization (FISH)
It is utilized to diagnose genetic diseases, gene mapping, and identification of chromosomal abnormalities, and may also be used to study comparisons among the ...
[71]
FISH – AMNIOTIC FLUID - Department of Pathology and Laboratory ...
FISH is a sensitive method to detect chromosome abnormalities. Because of its ability, FISH can detect the most common aneuploidy in uncultured amniocytes ...<|separator|>
[72]
Fluorescence In situ Hybridization: Cell-Based Genetic Diagnostic ...
Sep 4, 2016 · FISH technology enabled the detection of an increased spectrum of genetic disorders from chromosomal abnormalities to submicroscopic copy ...Abstract · Cell Based Genetic Diagnosis... · Single-Cell DNA Structural...
[73]
Array-based high-throughput DNA markers for crop improvement
May 7, 2008 · These microarray-based markers are the markers of choice for the future and are already being used for construction of high-density maps, quantitative trait ...
[74]
High-Throughput Sequencing Technologies - PMC - NIH
High-throughput sequencing offers many advantages over DNA microarrays. In particular, it is more precise and not subject to cross-hybridization, thereby ...
[75]
Overview of ELISA | Thermo Fisher Scientific - US
ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins ...
[76]
ELISA vs Western Blot: When to Use Each Immunoassay Technique
ELISA is a highly sensitive, specific, and versatile technique that can detect proteins in complex biological samples, even at nanomolar concentrations.
[77]
Protein recognition methods for diagnostics and therapy - PMC
Enzyme-linked immunosorbent assays (ELISA) and western blotting rely on the specific binding between antibodies and antigens to detect and quantify proteins.
[78]
ELISA vs Mass Spectrometry: Choosing a Protein Quantitation Method
Mass spectrometry directly measures proteins, while ELISA uses antibodies for indirect, sensitive quantitation in large sample numbers. ELISA is simple and ...
[79]
Proteomics Discovery of Disease Biomarkers - PMC - NIH
Examples of two promising proteomics technologies are mass spectrometry, including an instrument based on surface enhanced laser desorption/ionization, and ...
[80]
Proteomics reveal biomarkers for diagnosis, disease activity and ...
Oct 30, 2023 · Sensitive and reliable protein biomarkers are needed to predict disease trajectory and personalize treatment strategies for multiple sclerosis (MS).
[81]
Mass spectrometry-based proteomics as an emerging tool in clinical ...
Aug 26, 2023 · For example, in expression proteomics-based biomarker discovery, biomarkers are detected through comparison of protein expression profile ...
[82]
Proteomics Applications in Health: Biomarker and Drug Discovery ...
Expression of proteomics provides biomarker detection through comparison of protein expression profile between normal samples vs. disease affected ones. The ...
[83]
Prostate-Specific Antigen–Based Screening for Prostate Cancer ...
May 8, 2018 · PSA screening may reduce prostate cancer mortality risk but is associated with false-positive results, biopsy complications, and overdiagnosis.<|separator|>
[84]
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in ...
May 15, 2022 · Conclusions. Complementary approaches to quantifying overdiagnosis indicate a harm-benefit tradeoff of prostate-specific antigen screening that ...
[85]
evidence suggests that PSA testing leads to “overdiagnosis” of cancer
“This study shows that a substantial minority of the observed excess of cases in recent years is likely to be due to PSA testing. A majority of the observed ...
[86]
Lessons From U.S. Prostate Cancer Incidence Trends | JNCI
Background: Overdiagnosis of clinically insignificant prostate cancer is considered a major potential drawback of prostate-specific antigen (PSA) screening.
[87]
Immunoassay or molecular diagnostic? Context is everything
Jul 29, 2021 · Molecular assays offer high sensitivity/specificity but can be slower, while immunoassays are faster but may have reduced sensitivity. Clinical ...
[88]
Choosing Between Immunoassays and Molecular Assays - iFyber
Nov 1, 2023 · Immunoassays measure proteins/antigens, are faster, and used for clinical labs. Molecular assays are for genetic testing, are more sensitive, ...
[89]
Proteomic approaches for biomarker discovery and clinical ...
Proteomic biomarker panels are increasingly used for differential diagnosis, disease monitoring, and therapeutic decision-making in clinical settings.
[90]
Enzyme Linked Immuno Mass Spectrometric Assay (ELIMSA)
Mass spectrometry combined with the enzyme amplification in ELISA provides absolute sensitivity to detect attomol of PSA and was comparable to, or more ...Enzyme Linked Immuno Mass... · Abstract · Introduction
[91]
CRISPR-based diagnostics | Nature Biomedical Engineering
Jul 16, 2021 · In this Review, we provide a rundown of the rapidly expanding toolbox for CRISPR-based diagnostics, in particular the various assays, ...
[92]
SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential ...
Nov 4, 2020 · This review describes SHERLOCK and DETECTR technologies and assesses their properties, functions, and prospective to become the ultimate ...
[93]
CRISPR-Based Diagnostics: The Future of Disease Detection
Feb 24, 2025 · SHERLOCK and DETECTR were rapidly adapted for SARS-CoV-2 detection, offering rapid and accurate results5,6. Studies demonstrated high ...What is CRISPR diagnostics? · Notable CRISPR diagnostics...
[94]
CRISPR for companion diagnostics in low-resource settings
Sep 5, 2024 · SHERLOCK was tested for its ability to detect Zika and Dengue viruses in clinical isolates, genotype bacteria, and detect single-nucleotide ...
[95]
Evaluation of CRISPR-Based Assays for Rapid Detection of SARS ...
The results indicated that the sensitivity of CRISPR-based methods for diagnosis was 0.94 (95% CI 0.93–0.95), the specificity was 0.98 (95% CI 0.97–0.99), the ...
[96]
Evaluation of the diagnostic efficacy of CRISPR-based tuberculosis ...
CRISPR diagnostics exhibited the highest sensitivity (0.660) across all tests, while GeneXpert MTB/RIF demonstrated perfect specificity (0.986). Innowave DX MTB ...
[97]
Recent developments and future directions in point-of-care ... - NIH
Jan 9, 2025 · Sensitive diagnostic techniques like SHERLOCK and DETECTR can accurately identify malaria DNA or RNA patterns using CRISPR enzymes such as Cas12 ...
[98]
CRISPR‐driven diagnostics: Molecular mechanisms, clinical efficacy ...
Sep 26, 2025 · Cutting‐Edge Innovations: Covers key advances like amplification‐free detection, portable device integration, and multiplex platforms.
[99]
https://www.sciencedirect.com/science/article/pii/S0956566325010164
[100]
Exploiting the Specificity of CRISPR/Cas System for Nucleic Acids ...
Jan 9, 2024 · Both Cas enzymes demonstrate exceptional specificity and sensitivity, holding substantial promise in disease diagnostics and beyond.
[101]
Recent Advancements in Reducing the Off-Target Effect of CRISPR ...
Jan 18, 2024 · In this review, we summarize the recent technological advancements in reducing the off-target effect of CRISPR-Cas9 genome editing.
[102]
Diagnosing rare diseases after the exome - PMC - NIH
Over the past decade, exome sequencing has emerged as a comprehensive and cost-effective approach to identify pathogenic variants in the protein-coding regions ...
[103]
Next generation sequencing‐based gene panel tests for the ... - NIH
Cancer gene panel testing allows us to analyze genetic mutations treatable with molecular‐targeted drugs, and explore the possibility of increased control over ...
[104]
Confirming Variants in Next-Generation Sequencing Panel Testing ...
All variants demonstrated 100% concordance between NGS and Sanger sequencing ... Targeted next-generation sequencing can replace Sanger sequencing in clinical ...
[105]
Standardization of Sequencing Coverage Depth in NGS - Frontiers
Sep 3, 2019 · Conventional intrinsic NGS error rates range between 0.1 and 1% (Phred quality score of 20–30) (1, 11) depending on the sequencing platform, ...Introduction · NGS Sequencing Depth and... · Minimum Sequencing... · Discussion
[106]
Liquid biopsy for early detection of lung cancer - PMC - NIH
Mutation analysis of ctDNA In 2016, the FDA approved the first liquid biopsy genetic test for NSCLC—Cobas EGFR Mutation Test v2 liquid biopsy test from Roche ...
[107]
FDA approves liquid biopsy NGS companion diagnostic test for ...
Nov 9, 2020 · On November 6, FDA approved the FoundationOne Liquid CDx test as a companion diagnostic device to identify mutations in BRCA1, BRCA2 and ATM ...Missing: 2016 | Show results with:2016
[108]
Standards and Guidelines for the Interpretation of Sequence Variants
The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants.1 In the past decade, ...
[109]
Molecular Point of Care - Roche Diagnostics
Molecular Point of Care (POC) testing enables quick, accurate diagnoses at the site of care, using PCR technology for results in 20 minutes or less.Missing: NGS | Show results with:NGS
[110]
Portable molecular diagnostic platform for rapid point-of-care ...
Mar 24, 2025 · The Dragonfly workflow includes power-free extraction of nucleic acids in under 5 minutes, followed by colour-based molecular detection in less ...Missing: handheld NGS
[111]
Easy Fast Molecular Diagnostic Tests | QIAstat-Dx - QIAGEN
QIAstat-Dx tests have less than one minute hands-on time, results in about an hour, and require minimal training with no precision pipetting.<|separator|>
[112]
Integrated Point-of-Care Molecular Diagnostic Devices for Infectious ...
Nov 16, 2021 · Blood, nasal swab, saliva, urine, and stool are emphasized as the most commonly used clinical samples for integrated POC molecular diagnostics ...
[113]
Cepheid's Global Access Program - Tuberculosis
Cepheid's groundbreaking Xpert MTB/RIF test was a significant TB diagnostic innovation in nearly a century, and was quickly endorsed by the WHO1 and heralded by ...
[114]
WHO ENDORSES NEW RAPID TUBERCULOSIS TEST
Dec 8, 2010 · WHO's endorsement of the rapid test, which is a fully automated NAAT (nucleic acid amplification test) follows 18 months of rigorous assessment ...
[115]
GeneXpert for TB diagnosis: planned and purposeful implementation
Mar 21, 2013 · In December 2010, the World Health Organization (WHO) endorsed Xpert for the rapid and accurate detection of TB, particularly among PLHIV and ...
[116]
World's Most Portable Molecular Diagnostics System Unveiled at ...
Jul 28, 2015 · GeneXpert Omni to Further Decentralize Critical TB, Virology and Ebola Tests ... endorsed by the World Health Organization in December 2010.
[117]
Portable PCR Machines - Biocompare
Portable PCR machines are compact thermocyclers for PCR/qPCR in mobile settings, offering high performance, robust sensitivity, and fast amplification.
[118]
Molecular | Axxin
Highly flexible & portable real-time isothermal amplification platform with 2 channel fluorescence & 8 tube format for benchtop, field deployed, and PoC ...
[119]
The Evolving Synergy of POCT and NGS - Meridian Bioscience
The synergy between POCT and NGS combines comprehensive genomic analysis with rapid response, enabling in-depth genetic analysis with quick turnaround times.Missing: handheld | Show results with:handheld
[120]
Molecular Diagnostics in 2025 - IQVIA
May 22, 2025 · In early 2025, Roche received FDA clearance and CLIA waiver for cobas® liat CTNG & CTNG/MG, while bioMérieux is making notable progress with its ...
[121]
Impact of molecular point‐of‐care testing on clinical management ...
We investigated the potential impact of molecular point‐of‐care (POC) diagnostics on patient management and in‐hospital costs. Method. Prospective collection of ...
[122]
Cost-effectiveness of point-of-care diagnostics for AMR: a systematic ...
Mar 18, 2024 · Some POCTs are cost-effective in reducing antimicrobial prescribing, with 10 being cost-effective at £33.80 per avoided prescription. 18 ...
[123]
Cost-of-illness comparison between clinical judgment and molecular ...
Jan 17, 2023 · This study aims to demonstrate that the use of point-of-care testing (POCT) produces lower costs of illness compared to the costs incurred by relying on ...Missing: empirical outbreaks
[124]
Multiplex PCR system for the rapid diagnosis of respiratory virus ...
With the use of a mPCR panel, one study demonstrated a 30% to 50% increase in the diagnostic yield of respiratory viruses compared to direct fluorescent ...Missing: efficacy | Show results with:efficacy
[125]
Application of metagenomic next-generation sequencing in the ...
Nov 15, 2024 · However, mNGS is suitable for identification of unknown pathogens, analysis of complex microbial communities, detection of infectious diseases, ...
[126]
Metagenomic Next-Generation Sequencing of Nasopharyngeal ...
Nov 20, 2020 · This work illustrates the utility of mNGS for the detection and analysis of SARS-CoV-2 from NP swabs without viral target enrichment or amplification.
[127]
Metagenomic sequencing uncovers SARS-CoV-2 co-infections
Jun 15, 2020 · Metagenomic next-generation sequencing detects infection with emerging zoonotic disease and identifies co-infections that may increase ...
[128]
Establishing Ebola Virus Disease (EVD) diagnostics using ...
Jan 5, 2018 · Establishing Ebola Virus Disease (EVD) diagnostics using GeneXpert technology at a mobile laboratory in Liberia: Impact on outbreak response, ...<|control11|><|separator|>
[129]
Laboratory Response to Ebola — West Africa and United States - CDC
Jul 8, 2016 · This report compares CDC's domestic and international laboratory response engagements and lessons learned that can improve future responses.<|separator|>
[130]
False-Negative RT-PCR Findings and Double Mutant Variant ... - NIH
Sep 21, 2021 · This unexpected exponential surge of cases can be attributed to the rampant false-negative results of COVID-19 in the country and the newly identified B.1.617.
[131]
Impact of SARS-CoV-2 Mutations on PCR Assay Sequence Alignment
Such routine assessment can also potentially highlight false negatives in test samples that may be indicative of mutations having functional consequences in the ...<|separator|>
[132]
Molecular diagnostics for genotypic detection of antibiotic resistance
Feb 17, 2023 · This review provides an overview of commercially available genotypic assays that detect individual resistance genes and/or resistance-associated mutations.
[133]
Paving the way for precise diagnostics of antimicrobial resistant ...
Aug 11, 2022 · Offering speed and accuracy advantages compared with the traditional gold-standard phenotypic assay, molecular detection on the genetic ...
[134]
Rapid Detection of Staphylococcus aureus and Methicillin-Resistant ...
Mar 1, 2009 · Sensitivity was 97.1% and 98.3% for MRSA in wound and blood cultures, respectively; sensitivity was 100% for S. aureus from both wound and blood ...
[135]
Rapid molecular tests for detection of antimicrobial resistance ...
Conclusions. Our findings show that the Verigene and FilmArray systems may be a valid adjunct to the conventional microbiology (phenotypic or genotypic) methods ...
[136]
Molecular Methods for Detection of Antimicrobial Resistance
In this article we describe some of the common molecular methods currently used for detection of AMR genes. These include PCR, DNA microarray, whole-genome ...
[137]
The Genotype-to-Phenotype Dilemma: How Should Laboratories ...
May 19, 2021 · An important limitation of rapid genotypic AMR detection using molecular panels is the potential discrepancies that may arise upon performing ...
[138]
Phenotype–genotype discordance in antimicrobial resistance ...
Sep 23, 2025 · This study shows that there is phenotype–genotype discordance in AMR profiling among CAUTI isolates, highlighting the need for comprehensive ...
[139]
Molecular profiling in lung cancer | memo - Magazine of European ...
Jul 19, 2022 · In NSCLC, key molecular alterations include EGFR, BRAFV600E, KRASG12C, and ERBB2 (HER2) mutations, ALK, ROS1, NTRK 1/2/3, and RET fusions as ...
[140]
Molecular profiling for precision cancer therapies - Genome Medicine
Jan 14, 2020 · It therefore provides a more efficient, cost- and tissue-saving tumor analysis as compared to serial single-biomarker analyses [17, 18], ...
[141]
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell ...
Nov 18, 2017 · Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation–positive advanced NSCLC.
[142]
Emerging molecular testing paradigms in non-small cell lung cancer ...
Mar 24, 2025 · This review presents the currently known actionable mutations in lung cancer and new upcoming ones that are likely to enter clinical practice soon.
[143]
ESMO recommendations on microsatellite instability testing for ...
ESMO recommendations to assess MSI/dMMR as a predictor for immunotherapy are to use immunostaining for MMR proteins and microsatellite-PCR for sporadic cancers ...
[144]
Biomarkers of Response and Resistance to Immunotherapy in ...
Immune Checkpoint Inhibitors (ICIs) have demonstrated clinical efficacy in Microsatellite Instability High Colorectal Cancer (MSI-H CRC).
[145]
Cancer driver mutations: predictions and reality - PMC
Jul 7, 2025 · In this review we summarize the most recent efforts to identify driver mutations in cancer and annotate their effects.
[146]
Cancer driver mutations: predictions and reality - ScienceDirect.com
We review here computational methods that predict driver mutations, identify mutational processes causing these mutations, and detect potential mutation-based ...
[147]
Liquid Biopsy to Detect Minimal Residual Disease - NIH
In this review, we focus on the detection of MRD through liquid biopsy in solid cancers, highlighting currently available methodologies and ongoing challenges.Missing: approvals | Show results with:approvals
[148]
A comprehensive overview of minimal residual disease in ... - Nature
Jun 13, 2025 · Similarly, the FDA-approved FoundationOne Liquid CDx™ (Foundation Medicine) achieves a LoD of 0.37–0.9% MAF, and has applications spanning NSCLC ...
[149]
Residual ctDNA after treatment predicts early relapse in patients ...
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
[150]
New Data Shows NeXT Personal® Identifies Breast Cancer Patients ...
Jun 2, 2025 · Post-NAT ctDNA status was highly prognostic. Patients with ctDNA detected post-NAT were ~36 times more likely to have a distant relapse than ...
[151]
Guardant Health Guardant360® CDx First FDA-Approved Liquid ...
Aug 7, 2020 · Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw.
[152]
Liquid Biopsy Approaches for Cancer Characterization, Residual ...
Apr 30, 2025 · Although there are currently no FDA-approved ctDNA assays for MRD detection, certain Clinical Laboratory Improvement Amendments-/College of ...
[153]
Cancer in a drop: Advances in liquid biopsy in 2024 - PubMed
May 28, 2025 · Since 2020, publications on LB in solid tumors have doubled, underscoring its pivotal role in advancing cancer care. Notably, 2024 marked a peak ...
[154]
Circulating tumor DNA to monitor treatment response in ... - Nature
Mar 24, 2025 · With the advent of NGS, sequencing-based methods for ctDNA analysis in NSCLC gained traction. Notably, in 2014, Newman et al. introduced CAPP- ...
[155]
Circulating tumor DNA: current challenges for clinical utility - JCI
Jun 15, 2022 · These studies also highlighted some of the limitations of ctDNA, including that some cancer types may secrete or shed less DNA into the ...
[156]
Next-Generation Molecular Residual Disease Assays: Do We Have ...
May 16, 2024 · MRD detection requires sufficient sensitivity to capture low levels of ctDNA to enable detection of clinically occult metastatic disease in ...
[157]
Circulating tumour DNA-Based molecular residual disease detection ...
Apr 13, 2024 · More and more studies have demonstrated that circulating tumour DNA (ctDNA)-MRD (minimal residual disease) analysis can detect recurrence earlier than imaging.
[158]
ESMO recommendations on the use of circulating tumour DNA ...
ctDNA testing also has some limitations compared with tissue testing, mainly higher rates of false negatives and positives as discussed in prior sections, but ...
[159]
Molecular Genetics Testing - StatPearls - NCBI Bookshelf
Mar 16, 2024 · Molecular genetics testing is fundamental in evaluating inherited disorders, somatic or acquired diseases with genetic associations, ...
[160]
Genetic disorders: monogenic, polygenic and chromosomal disorders
Oct 12, 2022 · Genetic disorders are grouped according to whether the sequence changes occur in one gene, multiple genes or in chromosomes.
[161]
Carrier Screening - NTSAD
Aug 13, 2024 · ... reduce the incidence of Tay-Sachs disease in the Jewish population. The number of babies born with Tay-Sachs has been reduced by over 90% in ...
[162]
Beyond the “Jewish panel”: the importance of offering expanded ...
For example, the incidence of children born with Tay-Sachs disease decreased by more than 90% from the 1970s to 2000 owing to the development of screening ...
[163]
Association Between Carrier Screening and Incidence of Cystic ...
Dec 16, 2009 · The increase in the number of screened carriers over time was significantly correlated with the decrease in CF birth incidence.
[164]
The impact of a national population carrier screening program on ...
Conclusions. PCS markedly reduced CF birth rates with a shift towards milder mutations, but was often avoided for cultural reasons. As children regularly have ...
[165]
Systematic design and comparison of expanded carrier screening ...
Introduced in 2009, “expanded” carrier screening (ECS), which identifies reproductive risks for dozens to hundreds of diseases, has gained acceptance as a ...
[166]
Expanded carrier screening: What conditions should we screen for?
Jan 9, 2023 · Carrier screening tests reproductive couples for their risk of having children affected by serious monogenic conditions. Carrier screening ...HISTORY OF CARRIER... · PRINCIPLES OF ECS · RECOMMENDATION FOR...
[167]
Impact of a national genetic carrier‐screening program for ...
Apr 3, 2020 · The first tests implemented for carrier screening in Israel were biochemical testing for Tay-Sachs disease for the Ashkenazi Jewish population ...Abstract · INTRODUCTION · RESULTS · DISCUSSION
[168]
Non-invasive prenatal testing: use of cell-free fetal DNA in Down ...
NIPT has been widely validated, including comparison with standard prenatal aneuploidy screening, and has been shown to be a highly accurate screening test with ...
[169]
Commercial landscape of noninvasive prenatal testing in the United ...
May 17, 2013 · Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening.
[170]
Accuracy of non-invasive prenatal testing using cell-free DNA for ...
NIPT using cell-free fetal DNA has very high sensitivity and specificity for Down syndrome, with slightly lower sensitivity for Edwards and Patau syndrome.Missing: commercialization | Show results with:commercialization
[171]
Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Apr 1, 2015 · The positive predictive value for cfDNA testing was 80.9% (95% CI, 66.7 to 90.9), as compared with 3.4% (95% CI, 2.3 to 4.8) for standard ...
[172]
Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and ...
Jun 4, 2020 · Technological advances have enabled to make a diagnosis of CF with a sensitivity of 99% by using next generation sequencing in a single step.
[173]
Cystic fibrosis carrier screening in a North American population
Dec 19, 2013 · Although the detection rate for non-Hispanic whites is 88%, the detection rates for Hispanic-American (72%), African-American (64%), and Asian- ...
[174]
Cystic Fibrosis Carrier Screening and Diagnostic Testing
Cystic Fibrosis Carrier Screening ; Non-Hispanic Caucasian, 1/25, 97-98% ; Hispanic American, 1/58, 97-98% ; African American, 1/61, 97-98% ; Asian American, 1/94 ...
[175]
Preimplantation genetic testing for aneuploidies (abnormal number ...
Sep 8, 2020 · The evidence suggests that for the observed average cLBR of 29% in the control group, the chance of live birth following the results of one IVF ...
[176]
In Vitro Fertilization with Preimplantation Genetic Screening
Jul 5, 2007 · Preimplantation genetic screening did not increase but instead significantly reduced the rates of ongoing pregnancies and live births after IVF ...
[177]
Systematic review and meta-analysis: does pre-implantation genetic ...
Jul 22, 2023 · Thus, the analysis demonstrated an overall reduction in live birth rates following PGT-A when comparing like-for-like groups [18]. A separate ...
[178]
Table of Pharmacogenomic Biomarkers in Drug Labeling - FDA
Sep 23, 2024 · The table below lists therapeutic products from Drugs@FDA with pharmacogenomic information found in the drug labeling.
[179]
Codeine Therapy and CYP2D6 Genotype - NCBI - NIH
Sep 20, 2012 · The CYP2D6 enzyme converts codeine into its active metabolite, morphine, which provides its analgesic effect. Consequently, pain relief may be ...
[180]
CPIC® Guideline for Pharmacogenetics-Guided Warfarin Dosing
Dosing recommendations for warfarin dosing ... Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing ...
[181]
[PDF] Table of Pharmacogenomic Biomarkers in Drug Labeling - FDA
Aug 17, 2018 · In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent ...
[182]
Warfarin Therapy and VKORC1 and CYP Genotype - NCBI - NIH
Mar 8, 2012 · The label provides 2 sets of warfarin dosing recommendations, for when the CYP2C9 and VKORC1 genotypes are either known (Table 1) or not known ( ...Introduction · Drug: Warfarin · Gene: VKORC1 · Therapeutic...
[183]
Clinical Pharmacogenetics Implementation Consortium Guidelines ...
The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 geno-type data for estimating therapeutic warfarin dose.
[184]
Utilizing Pharmacogenomics to Reduce Adverse Drug Events
Dec 22, 2020 · Evidence shows that the use of PGx test results can prevent about 20 to 30 percent of ADEs and considerably reduce ADE-associated deaths.
[185]
Adverse drug reactions reduced by nearly one third after genetic ...
Nov 14, 2022 · “The underlying message is that, by undertaking the pharmacogenomic panel approach, we were able to reduce ADRs [adverse drug reactions] by 30%, ...
[186]
Pharmacogenomics for Improved Outcomes and Decreased Costs ...
Dec 15, 2023 · As mentioned earlier, PGx testing can reduce ADR risk by up to 30%. 4 These results were demonstrated in a prospective study conducted across 7 ...Pharmacogenomics · Pgx Testing · Improved Outcomes And Cost...
[187]
Genetic Factors in Drug Metabolism | AAFP
Jun 1, 2008 · The activity of drug-metabolizing enzymes may be induced or inhibited by many other intrinsic and extrinsic factors, including comorbid ...
[188]
Opportunities and obstacles in genotypic prediction of cytochrome ...
Because metabolic phenotype is subject to environmental exposures (concomitant disease(s) and drug therapy, dietary or lifestyle choices), genetic predictions ...
[189]
The needs and gaps in pharmacogenomics knowledge and ... - NIH
Nov 11, 2024 · Lack of pharmacogenomics knowledge among healthcare professionals is the most significant cited barrier to implementing pharmacogenomics in ...
[190]
Progress in Pharmacogenomics Implementation in the United States ...
Jun 4, 2025 · One of the main barriers to the widespread adoption of pharmacogenetic testing has consistently been limited and variable payer coverage.
[191]
Dynamics of cell-free tumor DNA correlate with early MRI response ...
Nov 6, 2024 · Furthermore, weekly monitoring enabled a detailed view on ctDNA dynamics and correlations with corresponding MR imaging during treatment.
[192]
ctDNA response after pembrolizumab in non-small cell lung cancer
Oct 9, 2023 · ctDNA response has been shown to predict outcome with immune checkpoint blockade, such that patients with NSCLC with stable disease that cleared ...
[193]
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes
May 6, 2025 · The study found that patients with ctDNA clearance within the first 10 weeks of treatment had better OS and PFS outcomes than patients who had ...Missing: 2020s | Show results with:2020s
[194]
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Mar 28, 2018 · The detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival ...
[195]
2021 Update on MRD in acute myeloid leukemia - ASH Publications
Dec 30, 2021 · Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, ...
[196]
Sensitivity, specificity and likelihood ratios of PCR in the ... - PubMed
Sep 28, 2012 · Objective: To systematically review and estimate pooled sensitivity and specificity of the polymerase chain reaction (PCR) technique ...
[197]
Accuracy of molecular diagnostic techniques in patients with a ...
In multiplex polymerase chain reaction (PCR) meta-analysis, overall sensitivity was 0.80 (95% confidence interval [CI] 0.73-0.86) and specificity was 0.83 (95% ...
[198]
PCR in diagnosis of invasive aspergillosis: a meta ... - PubMed
We performed a bivariate meta-analysis of diagnostic data for an Aspergillus sp. PCR assay with blood specimens from high-risk hematology patients.
[199]
Evaluating the performance of low-frequency variant calling tools for ...
Nov 22, 2023 · However, the detection of significant variants down to 1% has been impeded by the high error rate (0.1–1%) of NGS technologies.
[200]
Recommendations for Next-Generation Sequencing Germline ...
May 17, 2023 · The overall rate of NGS FPs varied considerably, likely reflecting variant calling and filtering differences that could impact sensitivity. The ...<|separator|>
[201]
Estimate false‐negative RT‐PCR rates for SARS‐CoV‐2. A ...
Nov 5, 2021 · This systematic review showed that up to 58% of COVID-19 patients may have initial false-negative RT-PCR results, suggesting the need to implement a correct ...
[202]
SARS-CoV-2 RT-qPCR Test Detection Rates Are Associated with ...
The overall detection rate in tests performed within 14 days after diagnosis was 83.1%. This rate was higher at days 0 to 5 after diagnosis (89.3%).
[203]
Meta-analysis of the robustness of COVID-19 diagnostic ... - BMJ Open
We reviewed 85 studies (21 530 patients), published from five regions of the world, to highlight issues involved in the diagnosis of COVID-19 in the early ...<|separator|>
[204]
High heterogeneity undermines generalization of differential ...
Jan 28, 2021 · High heterogeneity in gene expression, caused by tumor heterogeneity, leads to poor reproducibility of DE results in RNA-Seq, undermining ...
[205]
Clinical implications of intratumor heterogeneity: challenges and ...
Jan 22, 2020 · In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses.<|control11|><|separator|>
[206]
Biologically Relevant Heterogeneity: Metrics and Practical Insights
Heterogeneity is a fundamental property of biological systems at all scales that must be addressed in a wide range of biomedical applications.
[207]
Assessing the Cost-Effectiveness of Next-Generation Sequencing as ...
NGS reduces turnaround time and costs vs conventional molecular tests. Pennell et al, 2019, United States, NSCLC, Targeted panel (8 genes), 2860 USD, 3342 USD ...
[208]
Molecular Testing in Point-of-Care (POC) | myadlm.org
Jul 16, 2025 · These assays retain sensitivity and specificity while reducing costs and turnaround times.3 There is also equipment-free molecular POC testing.
[209]
Real-world trends in costs of next generation sequencing (NGS ...
Aug 10, 2025 · Mean cost of NGS testing has been estimated at $4932 per patient [67]; however, large healthcare systems in the United States provide only ...
[210]
Unlocking the health system barriers to maximise the uptake and ...
In this paper, we focus on health system challenges and show that uptake and utilisation of molecular and microbiological (culture) diagnostics in LMIC setting ...
[211]
A qualitative systematic review of barriers and facilitators to the ...
Infrastructure emerged as a critical determinate in implementing molecular diagnostic devices, highlighting challenges with limited physical space, unreliable ...
[212]
Sample-to-result molecular diagnostic platforms and their suitability ...
May 15, 2024 · For many diseases, molecular diagnostics are the gold standard, but are not easy to implement in Low- and Middle-Income Countries (LMIC). Sample ...
[213]
Molecular diagnostics market growth at CAGR of 6.2%
The global molecular diagnostics market growth is estimated at CAGR of 6.2% during the forecast period 2024-2035, with market reaching over USD 30.9 billion ...
[214]
Next Generation Sequencing Services Market by Size, Share, Forecast
According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome decreased from USD 29,092 in 2010 to USD 562 in 2021.
[215]
Molecular Diagnostics Market Size | Industry Report, 2030
The global molecular diagnostics market size was estimated at USD 25.75 billion in 2024 and is projected to reach USD 33.08 billion by 2030, growing at a CAGR ...
[216]
Leveraging Molecular Diagnostic Technologies to Close the Global ...
Oct 17, 2022 · We provide a framework for how stakeholders can leverage molecular diagnostics to advance cancer care in LMICs moving forward.
[217]
The challenge of genetic variants of uncertain clinical significance
Genomic tests expand diagnostic and screening opportunities but also identify genetic variants of uncertain clinical significance (VUS).
[218]
Variants of uncertain significance in the era of high-throughput ...
Mar 4, 2020 · High-throughput sequencing, or Next-Generation Sequencing (NGS), has improved cancer patient management, ameliorating diagnosis and treatment ...
[219]
the challenges of genetic variants of uncertain significance in clinical ...
Jan 22, 2018 · VUSs are genetic findings with unresolved clinical significance, creating challenges for clinicians and patients, who may experience ...
[220]
Frequency of genomic incidental findings among 21,915 eMERGE ...
The overall frequency of incidental findings was 3.02%, with 2.54% from 59 recommended genes and 0.48% from other genes.
[221]
Major Causes of Conflicting Interpretations of Variant Pathogenicity ...
Aug 15, 2024 · We found that 5.7% of variants have conflicting interpretations (COIs) reported, and the vast majority of interpretation conflicts arise for variants of ...
[222]
A Targeted Methylation–Based Multicancer Early Detection Blood ...
Aug 29, 2024 · In oncology, overdiagnosis of prostate cancer (PCa) is a common problem, estimated to account for 23%-42% of all screen-detected cases. This ...
[223]
Genetic risk scores may compound rather than solve the issue of ...
Nov 28, 2022 · Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis. Br J Cancer 128, 1–2 (2023). https://doi.org ...
[224]
Personalised Medicine: The Promise, the Hype and the Pitfalls
May 18, 2017 · While in both benign and malignant disease, diseases caused by single genetic alterations are more amenable to precision medicine approaches, ...
[225]
Standards and guidelines for the interpretation of sequence variants
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics
[226]
Precision medicine: hype or hope? - PMC - NIH
In order to reach this prediction for precision medicine, we as physicians need to use the science that is available, encourage and participate in basic and ...Missing: outcomes rates post-
[227]
Has the Promise of Precision Medicine Been Oversold?
Oct 25, 2018 · The ASCO Post held a wide-ranging and lively roundtable discussion exploring the promise vs the reality of precision medicine in current clinical care.Missing: rates | Show results with:rates
[228]
Evaluation of personalized cancer therapies based on ... - NIH
Considering 64 successful genomic profiles, in 63% actionable alterations were detected. In 20 patients 1 actionable mutation was found, in 14 patients 2 ...
[229]
Evolution of the Randomized Clinical Trial in the Era of Precision ...
Mar 25, 2021 · In this study, we describe the design and results of oncology RCTs conducted during 2010 to 2020 in the era of precision oncology. We compare ...
[230]
Clinical benefits of precision medicine in treating solid cancers ...
In this study, we showed that precision and matched cancer therapies are still underdeveloped with respect to clinical benefit values.
[231]
Performance of polygenic risk scores in screening, prediction, and ...
Polygenic risk scores performed poorly in population screening, individual risk prediction, and population risk stratification.
[232]
Polygenic risk scores: from research tools to clinical instruments
May 18, 2020 · We focus on two limitations to the implementation of polygenic risk scores in clinical practice: firstly, the weaker evidence base in ...
[233]
Cancer survival statistics for patients and healthcare professionals ...
Jul 13, 2020 · ... for in the era of precision medicine. And although beyond the scope of this review, machine learning algorithms, particularly deep learning ...Missing: post- | Show results with:post-
[234]
Precision oncology medicines and the need for real world evidence ...
Precision oncology has made remarkable strides in improving clinical outcomes, offering hope to patients with historically difficult-to-treat, ...<|control11|><|separator|>
[235]
Precision oncology: lessons learned and challenges for the future
Here, we review the current landscape of precision oncology and highlight challenges to be overcome and examples of benefits to patients.Missing: empirical | Show results with:empirical
[236]
The precarious future of consumer genetic privacy - Science
Sep 11, 2025 · After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people ...
[237]
23andMe fined £2.31 million for failing to protect UK users' genetic ...
Jun 17, 2025 · We have fined genetic testing company 23andMe £2.31 million for failing to implement appropriate security measures to protect the personal information of UK ...Missing: DTC | Show results with:DTC
[238]
Direct-to-Consumer Genetic Testing Data Privacy: Key Concerns ...
We discuss major challenges to upholding DTC-GT consumer expectations of privacy as a form of protection and provide recommendations.
[239]
The Challenge of Informed Consent and Return of Results in ... - NIH
They are occurring in the context of controversy over how to obtain consent for exome and genome sequencing, whether to return results, and the role of patient/ ...
[240]
ACMG recommendations for reporting of incidental findings in ...
The ACMG recommends that laboratories performing clinical sequencing seek and report mutations of the specified classes or types in the genes listed here.Missing: frequency | Show results with:frequency<|separator|>
[241]
Laboratory and Clinical Implications of Incidental and Secondary ...
Mar 26, 2021 · The most common type of anticipated incidental finding on tumor NGS testing is a potential germline variant within an ordered gene panel. The ...
[242]
Genetic Discrimination - National Human Genome Research Institute
Jan 6, 2022 · The Genetic Information Nondiscrimination Act (GINA) of 2008 protects Americans from discrimination based on their genetic information in both health insurance ...
[243]
The Genetic Information Nondiscrimination Act (GINA): Public Policy ...
This article examines the fear and reality of genetic discrimination in the United States, describes how Congress sought to prohibit such discrimination.
[244]
Genetic Information, Non-Discrimination, and Privacy Protections in ...
Despite lack of empirical evidence that discrimination is occurring, fear of genetic discrimination remains a barrier to the uptake of genetic testing, even in ...